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ABSTRACT 
GONADOTROPIN RELEASING HORMONE RECEPTOR LIGAND 
INTERACTIONS 
Colleen Anne Flanagan 
Department of Chemical Pathology, University of Cape Town 
August, 1995 
The decapeptide, gonadotropin releasing hormone (GnRH), is the central regulator of 
reproductive function. It binds to receptors on the gonadotrope cells of the pituitary and 
stimulates release of luteinizing hormone (LH) and follicle stimulating hormone (FSH). 
Eleven different structural forms of GnRH have now been identified in various animal 
species. Chimaeric analogues of some of the variant forms of GnRH were synthesized in 
order to study the functional significance of the most common amino acid substitutions, 
which occur in positions 5, 7 and 8. Peptide binding affinities for sheep and rat GnRH 
receptors and potencies in stimulating LH and FSH release from cultured sheep pituitary cells 
and LH release from cultured chicken pituitary cells were measured. Histidine in position 5 
decreased LH releasing potency in chicken cells, but slightly increased receptor binding 
affinity in rat and sheep membranes. Tryptophan in position 7 had minimal effect on GnRH 
activity in mammals, but increased LH release in chicken cells. Although differences in the 
structural requirements of mammalian and chicken GnRH receptors were anticipated, it was 
also found that rat GnRH receptors exhibited higher affinity for analogues with Tryptophan in 
position 7, than did sheep GnRH receptors. Substitutions in position 8 revealed the most 
marked differences in the structural requirements of mammalian and chicken GnRH 
receptors. Arginine was required for high GnRH activity in mammalian systems, but 
analogues with neutral substitutions in position 8 were more potent in chicken pituitary cells. 
The tolerance of position 8 substitutions, combined with the relatively small effects, in 
chicken cells, of incorporating a D-amino acid in position 6, indicate that the chicken GnRH 
receptor is less stringent than mammalian receptors in its recognition of peptide conformation. 
To examine how changes in ligand structure cause changes in receptor binding affinity 
and receptor activation, it was necessary to know the structures of the GnRH receptors. A 
protocol was developed for the purification of GnRH binding proteins from detergent-
solubilized pituitary membranes, by affinity chromatography. This procedure yielded a 
protein which migrated as a single band on sodium dodecyl sulfate polyacrylamide gel 
electrophoresis, but was different from the recently cloned GnRH receptor. 
To test the proposal that the arginine residue in mammalian GnRH interacts with an 
acidic receptor residue, eight conserved acidic residues of the cloned mouse GnRH receptor 
were mutated to asparagine or glutamine. Mutant receptors were transiently expressed in 
COS-1 cells and tested for decreased preference for Arg8-containing ligands by ligand 
binding and inositol phosphate production. One mutant receptor, in which the glutamate 
residue in position 301 was mutated, exhibited decreased affinity for mammalian GnRH. The 
mutant receptor also exhibited decreased affinity for [Lys8]-GnRH, but unchanged affinity for 
[Gln8]-GnRH compared with the wildtype receptor, and increased affinity for the acidic 
analogue, [Glu8]-GnRH. This loss of affinity was specific for the residue in position 8, 
because the mutant receptor retained hiszh affinity for analogues with favourable substitutions 
in positions 5, 6 and 7. Thus, the Glu30r residue of the GnRH receptor plays a role in receptor 
recognition of Arg8 in the ligand, consistent with an electrostatic interaction between these 
two residues. 
The Glu301 and Arg8 residues were not required for the high affinity interactions of 
conformationally constrained peptides. This indicates that an interaction which involves these 
two residues may induce changes in the conformation of GnRH after it has bound to the 
receptor. 

CHAPTER 1 
STRUCTURE AND FUNCTION OF GONADOTROPIN RELEASING HORMONE 
AND THE GONADOTROPIN RELEASING HORMONE RECEPTOR 
SUMMARY 
Gonadotropin releasing hormone (GnRH) regulates reproductive function by controlling 
the release of the two gonadotropic hormones, luteinizing hormone and follicle stimulating 
hormone. GnRH binds to receptors on the plasma membrane of pituitary gonadotrope cells 
and activates G-proteins which include the Gq class. The G-proteins, in turn, stimulate the 
effector enzyme, phospholipase C, to hydrolyze a membrane phospholipid, phosphatidyl 
inositol bisphospate, to generate the second messengers, inositol trisphosphate and 
diacylglycerol, which regulate cytosolic free calcium levels and protein kinase C. 
Eleven different GnRH structures have been identified in various animal species and 
they have varying activities in mammals and non-mammalian vertebrates. The GnRH peptide 
has no fixed conformation in solution. However, molecular dynamics simulations and 
molecular modelling, combined with the introduction of conformational constraints into 
synthetic GnRH analogues, have shown that GnRH probably interacts with its receptor in a 
conformation which incorporates a ~ bend centered around the glycine residue in position 6. 
Analysis of the contribution of individual amino acids to the activity of GnRH shows that, 
although no single residue is absolutely essential, the amino-terminal residues appear to have 
an important role in receptor activation, while the carboxy-terminal residues are necessary for 
high affinity binding to the receptor. 
Cloning of the GnRH receptor showed its structure to be typical of G-protein coupled 
receptors, comprising a single polypeptide chain with seven hydrophobic segments. It also 
has some atypical features including the lack of a hydrophilic carboxy-terminal domain, an 
unusually long first intracellular loop and the apparent interchange of two highly conserved 
residues, an aspartate which usually occurs in the second transmembrane helix and an 
asparagine usually found in the seventh. This natural reciprocal mutation has been exploited 
in experiments to define the three-dimensional conformation of the GnRH receptor and other 
G-protein coupled receptors. A lysine residue in the third transmembrane helix has been 
shown to affect binding of GnRH agonists, but not antagonists. Like other peptide receptors, 
the ligand binding site extends to the extracellular domain of the GnRH receptor, where an 
acidic residue in the third extracellular loop is important for ligand binding. Site-directed 
mutagenesis and studies with proteolytic enzymes have shown that the ligand binding domain 
for GnRH antagonists differs from that for GnRH agonists. 
2 
INTRODUCTION 
This chapter will only briefly describe the physiological role of GnRH in reproduction, 
its biosynthesis and the transduction of the GnRH signal to the interior of the cell. The 
structure of GnRH will be reviewed in more depth with a view to understanding which 
apsects of GnRH structure are important for its activity in binding and activating the pituitary 
GnRH receptor. The structure and function of the GnRH receptor will be discussed in 
comparison with the G-protein coupled receptors, to which it is related. 
PHYSIOLOGY AND CELL BIOLOGY OF GnRH 
The role of GnRH in reproduction 
Gonadotropin releasing hormone (GnRH) plays a central role in regulating animal 
reproduction. It is synthesized in the hypothalamic neurosecretory cells and released into 
portal vessels which connect the hypothalamic region of the brain with the pituitary gland. 
Thus it integrates the neural and endocrine systems (Millar and King, 1988; Hazum and 
Conn, 1988). In the pituitary it provokes the gonadotrope cells to release both of the 
gonadotropic hormones, luteinizing hormone (LH) and follicle stimulating hormone (FSH) 
(Schally et al., 1971a, 1971b, 1971c; Matsuo et al., 1971; Burgus et al., 1972) which in turn 
control the function of the gonads (ovaries and testes). LH stimulates ovulation and formation 
of the corpus luteum in females and androgen secretion in males, whereas FSH stimulates the 
growth and maturation of ovarian follicles in females and spermatogenesis in males. 
' 
In addition to stimulating release of gonadotropins, GnRH has other important actions 
on the pituitary. It regulates expression of GnRH receptors (Clayton, 1989; Young et al., 
1985) and modulates levels of GnRH receptor mRNA (Yasin et al., 1995). GnRH also 
regulates biosynthesis of LH, increasing levels of mRNA for the ~ subunit of LH (Clayton, 
1989 for review) and regulates glycosylation of LH, thus modifying its bioactivity (Azhar et 
al., 1978; Ramey et al., 1987). GnRH treatment also increases the size, secretory apparatus 
and number of gonadotropes (Clayton, 1989). GnRH actions are modulated by the gonadal 
steroids, estradiol, progesterone and testosterone (Clayton, 1989; Dalkin et al., 1989), and by 
the gonadal polypeptides, activ.in and inhibin, named for their effect on FSH secretion 
(Seeburg et al., 1987). 
GnRH biosynthesis 
In rat hypothalamus and in human hypothalamus and placenta, GnRH is synthesized as 
a 92-amino acid precursor (fig. 1.1) (Adelman et al., 1986; Seeburg and Adelman, 1984). The 
first 23 amino acids comprise the signal sequence which features a typical hydrophobic 
3 
-23 , , , , .-1 1 10 11 12 13 14 , ; , , 69 
Ket . . . .Se Gln Hi• Trp Ser Tyr Gly Leu Arg Pro Gl Gly LY• Arg Aap . . . Ile 
signal GnRH GAP 
Figure 1.1 Schematic diagram of the human pre-pro-GnRH, showing the signal sequence 
(-23 to -1), the GnRH sequence, the Gly residue involved in carboxy-tenninal amidation, the 
Lys-Arg processing site, and the 57-amino acid GnRH-associated peptide (GAP). 
middle section. The signal sequence is 60% homologous between rat and human hypothalami, 
and identical in human hypothalamus and placenta. It is followed by the decapeptide GnRH 
sequence and the Gly-Lys-Arg sequence necessary for enzymatic processing. It is likely that 
the precursor is processed by trypsin-like cleavage at the pair of basic amino acids, followed 
by removal of the exposed basic amino acids by carboxypeptidase B-like activity and 
amidation utilizing Glyll as the amide donor (Millar and King, 1987; Seeburg et al., 1987). 
The amino-terminal pyro-glutamate is formed by spontaneous cyclization of Gin (Millar and 
King, 1987; Seeburg et al., 1987). The remaining 57-amino acid GnRH-associated peptide 
has been reported to inhibit release of prolactin and to stimulate gonadotropin release 
(Nikolics et al., 1985; Phillips et al., 1985) via a mechanism independent of the GnRH 
receptor (Milton et al., 1986; Millar et al., 1986a). The effects of the GnRH-associated 
peptide are controversial and appear to require gap junctions and cell communication 
(Seeburg et al., 1987). 
Pulsatile release of GnRH 
GnRH is released from the hypothalamus in pulses (Carmel et al., 1976 and many 
others). The frequency and amplitude of these pulses vary, under neural control, with the 
oestrous and menstrual cycles (Fox and Smith, 1985; Daikin et al., 1989). Fast pulses of 
GnRH preferentially stimulate LH release. They also stimulate the synthesis of mRNA for the 
~ subunit of LH and for the a subunit which is common to both gonadotropic hormones. In 
contrast, slower pulses of GnRH favour the release of FSH and the synthesis of FSH ~ 
subunit mRNA. As the frequency of pulses of GnRH secretion changes in normal physiology, 
frequency modulation may be the mechanism by which a single hypothalamic releasing 
hormone regulates differential secretion of both LH and FSH (Dalkin et al., 1989). 
Intracellular transduction of the GnRH signal 
GnRH binds to a specific receptor on the plasma membrane of pituitary gonadotrope 
cells (Naor, 1990). Activation of the receptor is probably associated with a change in 
4 
GTP 
p. 
I 
Figure 1.2 The G-protein activation cycle 
showing the 3 different conformations of Ga and 
interactions with receptor and effector d~ng the 
GTPase cycle. See text for explanation. R , 
activated receptor, E, effector (based on Conklin 
and Bourne, 1993). 
confonnation (Samama et al., 1993), 
which transmits the binding signal _to 
the intracellular surface of the cell 
membrane and activates one or more 
guanine nucleotide binding proteins 
(G-proteins) (Andrews et al., 1986; 
Perrin et al., 1989; Limor et al., 1989). 
The G-proteins that transmit 
infonnation from cell membrane 
receptors to their intracellular 
effectors belong to a large 
homologous family of heterotrimeric 
proteins, consisting of a, ~ and 'Y 
subunits. The different G-proteins are 
most readily distinguished by their a 
subunits (table 1.1), although there are 
also less well characterized structural 
and functional differences in their~ and y subunits (faylor, 1990). The a subunits bind and 
hydrolyze GTP and contain the structural determinants of interaction with receptors and 
effector enzymes (Conklin and Bourne, 1993). The G-protein activation cycle is illustrated in 
fig 1.2. G-proteins bind to activated receptors in their trimeric form with GDP bound to the a 
subunit Activated receptors catalyze activation of G-proteins by increasing the rate of GDP 
' dissociation and allowing subsequent replacement of GDP with GTP (faylor, 1990; Conklin 
and Bourne, 1993). Binding of GTP causes the a subunit to take on a new confonnation and it 
rapidly dissociates from both the receptor and the 13-y complex (Conklin and Bourne, 1993). 
Both of the resulting free a.-GTP and 13-y subunits regulate intracellular effectors (Stemweiss 
and Smrcka, 1992; Exton, 1994). 
Although it has been suggested that multiple G-proteins are involved in GnRH signal 
transduction (Hawes and Conn, 1993; Hawes et al., 1993), only two, Gq and G 11, have been 
identified and the GnRH receptor does not appear to discriminate between them (Hsieh and 
Martin, 1992; Shah and Milligan.,. 1993; Shah et al., 1995). The GTP-bound a subunits of the 
Gq-proteins activate the ~ isoforms of the effector enzyme, phospholipase C (PLC). Activated 
aq and a 11 subunits stimulate the ~1 isoenzyme of PLC (Sternweiss and Smrcka, 1992; 
Exton, 1994). PLC hydrolyzes the membrane phospholipid phosphatidyl inositol 4,5-
bisphosphate (PIP:z) to generate the second messengers, inositol 1,4,5-trisphosphate (IP]) and 
diacylglycerol (DAG) (Andrews et al., 1986; Limor et al., 1989; Naor, 1990). The 
involvement of PLC in GnRH signal transduction was supported by early work which showed 
' 
5 
that GnRH increased phosphoinositide turnover (Kiesel and Catt, 1984; Andrews and Conn, 
1986; Naor et al., 1985), while later work demonstrated rapid hydrolysis of PIP2 in response 
to GnRH (Naor et al., 1986; Morgan et al., 1987; Naor, 1990). 
The LH secretory response to GnRH is biphasic: there is an initial rapid spike of LH 
release which is followed by a lower sustained plateau phase. The peak and plateau in LH 
release are preceded by similar changes in cytosolic free calcium concentration ([Ca2+]J. The 
peak and plateau in [Ca2+]i reflect a temporal sequence of calcium mobilization from 
intracellular stores followed by an influx of extracellular calcium (Catt and Stojilkovic, 1989). 
IP3, a second messenger generated by PLC, binds to intracellular receptors and mobilizes 
intracellular Ca2+ stores to produce the initial spike of [Ca2+]i (Guilemette et al., 1987; Naor 
et al., 1988; Catt and Stojilkovic, 1989; Naor, 1990). Toe second, plateau, phase of [Ca2+h 
elevation results from influx of extracellular ea2+ through at least two groups of "receptor-
operated" calcium channels. About 50% of calcium influx occurs through L-type, 
dihydropyridine sensitive, voltage sensitive calcium channels, while the remainder enters 
through dihydropyridine insensitive channels (Tasaka et al., 1988; Naor et al., 1988; 
Davidson et al., 1988; Catt and Stojilkovic, 1989; Naor, 1990; Davidson et al., 1991). The 
increased [Ca2+h leads to activation of the calcium binding protein calmodulin (Conn et al., 
Table 1.1 The family of G-Protein a subunits in mammals 
(based on Conklin and Bourne, 1993} 
Subfamily Ga Effectors Intracellular 
Message 
s adenyl cyclase ( +} cAMP 
Ca2+ channels (open} membrane 
potential (-} 
<lolf adenyl cyclase ( +} cAMP (+} 
i/o/t <lj,i2,i3 K+ channels (open} membrane 
potential ( +} 
Ca2+ channels (close} membrane 
potential (-} 
CXz adenyl cyclase (-} cAMP (-} 
cxt1 cGMP-phosphodiesterase cGMP (-} 
<lt2 cGMP-phosphodiesterase cGMP (-) 
°'gust unknown unknown 
q <Xq,11,14,15,16 phospholipase C 13 IP3 (+}, 
DAG(+} 
12/13 <X12,13 unknown unknown 
6 
1981a, 1981b; Jennes et al., 1985; Conn et al., 1985a). 
The other product of PLC activity, DAG, activates protein kinase C (PKC). However, 
there is controversy as to the importance of PKC activity in GnRH-stimulated LH release 
(Catt and Stojilkovic, 1989; Naor, 1990; Davidson et al., 1991). In favour of a role for PKC is 
the demonstration that phorbol esters and DAGs (PKC activators) stimulated LH release 
(Smith and Conn, 1984; Conn et al., 1985b; Harris et al., 1986), as did insertion of the 
enzyme into permeabilized PKC-depleted cells (Naor, 1990). GnRH also stimulates 
redistribution of PKC from the cytosol to the plasma membrane, the main mechanism of its 
activation (Hirota et al., 1985, Naor et al., 1985). Similar phosphoprotein substrates were 
identified in cultured pituitary cells which were stimulated with GnRH and with a phorbol 
ester. Phosphorylation of the GnRH substrates was inhibited in PKC-depleted cells and in the 
presence of a PKC inhibitor (Strulovici et al., 1987). However, in experiments using cells 
depleted of PKC by prolonged incubation with tetradecanoyl phorbol ester (TP A), a PKC 
activator and analogue of DAG, McArdle et al. (1987) reported that PKC depletion did not 
affect GnRH-stimulated LH release although others (Stojilkovic et al., 1988; Dan-Cohen and 
Naor, 1990) reported decreased response to GnRH. In addition, it was shown that a phorbol 
ester stimulated release of more LH than did GnRH and that the effects of simultaneous 
administration of phorbol ester and GnRH was additive (Beggs and Miller, 1989; Kile and 
Nett, 1994) or synergistic (Johnson et al., 1987). Also, inhibitors of PKC did not inhibit 
GnRH-stimulated LH release (Johnson et al., 1987; Beggs and Miller, 1989). Thus, it is likely 
that both elevation of [Ca2+]i and activation of PKC, are necessary to elicit the full GnRH 
response (Naor and Eli, 1985), and that PKC may amplify or modulate the calcium signal 
(Davidson et al., 1991). The major function of PKC may be to regulate the longer-term 
effects of GnRH, in particular gonadotropin gene expression (Andrews et al., 1988) and up-
regulation of the GnRH receptor (Conn, 1989). 
GnRH STRUCTURE AND THE RELATIONSHIP BETWEEN STRUCTURE AND 
ACTIVITY 
Structures of naturally occurring GnRHs 
The structure of GnRH was first determined from porcine hypothalamus (Matsuo et al., 
1971). Shortly thereafter, an identical structure was found in ovine (sheep) hypothalamus 
(Amoss et al., 1971; Burgus et al., 1972). The same GnRH structure was demonstrated in 
humans and rats (Adelman et al., 1986). Post-translationally modified [hydroxyproline9l-
GnRH was also found in extracts of mammalian hypothalamus (Gautron et al., 1991). Other 
forms of GnRH have been isolated from non-mammalian species and sequenced (table 1.2). 
Two forms were found in the chicken: [Gln8]-GnRH (chicken GnRH I) (King and Millar, 
7 
residue# 1 2 3 4 5 6 7 8 9 10 
spec1~s 
mammalian pGlu His Trp Ser Tyr Gly Leu Arg Pro GlyNH2 
hydroxy-Pro HOPro 
chicken I Gln 
sea bream Ser 
salmon Trp Leu 
catfish His Asn 
chicken II His Trp Tyr 
dogfish His Trp Leu 
lamprey ill His Asp Trp Lys 
lamprey I Tyr Leu Glu Trp Lys 
tunicate I Asp Tyr Phe Lys 
tunicate II Leu Cys His Ala 
Table 1.2 Comparison of variant GnRH structures with mammalian GnRH 
1982) and [His5,Trp7,Tyr8]-GnRH (chicken GnRH II) (Miyamoto et al., 1984). [Trp7,Leu8]-
GnRH (salmon GnRH) was sequenced from salmon brain (Sherwood et al., 1983) and 
[Tyr3,Leu5,Glu6,Trp7,Lys8]-GnRH (lamprey GnRH I) from lamprey (Sherwood et al., 1986). 
More recently, three novel forms of GnRH, [His5,Trp7,Leu8]-GnRH (dfGnRH) (Lovejoy et 
al., 1992), [His5,Asn8]-GnRH (cfGnRH) (Bogerd et al., 1992) and [Ser8]-GnRH (sbGnRH) 
(Powell et al., 1994), have been identified in dogfish, catfish and seabream respectively and 
another lamprey form ([His5,Asp6,Trp7,Lys8]-GnRH) has been found (Sower et al., 1993). 
Two forms of GnRH, [Asp5,Tyr6,Phe7,Lys8]-GnRH and [Leu5,Cys6,ffis7,Aia8]-GnRH, have 
recently been identified in an invertebrate, the tunicate (Sherwood, 1995). The brains of non-
mammalian vertebrates and some mammals (King et al., 1989; King et al., 1990; Dellovade 
et al., 1993; King et al., 1994) contain more than one molecular form of GnRH. It is believed 
that the different GnRHs have been co-opted for multiple functions in addition to 
gonadotropin release. Schemes suggesting the evolution of the different GnRH peptides have 
been presented (for reviews see King and Millar, 1987; Sherwood, 1987; King and Millar, 
1990, 1992). 
Certain structural features of the GnRH molecule have been conserved throughout the 
500 years of evolution separating lampreys and humans. Peptide length is conserved, since all 
of the characterized GnRH structures are decapeptides. The pGlu 1-ffis2 residues at the amino 
terminus, Ser4, and the Pro9-Glyl<>NH2 at the carboxy-terminus are conserved. The 
conservation of these features suggests that they could have significant functional roles (King 
and Millar, 1990). 
Activities of naturally occurring GnR.Hs 
In cultured mammalian (rat and sheep) pituitary cells, mammalian GnRH is highly 
potent and stimulates gonadotropin release at low doses. The LH releasing potency of chicken 
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GnRH II ([His5,Trp7,Tyr8]-GnRH) is about one third of that of mammalian GnRH, whilst the 
potencies of chicken GnRH I ([Gln8]-GnRH) and salmon GnRH ([Trp7,Leu8]-GnRH) are 
lower at 1 to 3 % and 2 to 5 % that of mammalian GnRH and lamprey GnRH I is inactive. 
This order of potency is also apparent in the abilities of the naturally occurring GnRHs to 
compete for binding to mammalian GnRH receptors (Millar and King, 1983a, 1983b; 
Sherwood et al., 1983; Miyamoto et al., 1984; Hasegawa et al., 1984). The reasons for these 
differences will be explored in chapter 2. 
The relationships between peptide structure and receptor binding or gonadotropin 
releasing activity are less well characterized in non-mammalian systems. In birds, mammalian 
GnRH and chicken GnRH I ([Gln8]-GnRH) have similar gonadotropin releasing activity in 
vitro (Millar and King, 1983a, 1983b; Hattori et al., 1985, Hasegawa et al., 1984, Johnson et 
al., 1984) and in vivo (Johnson et al., 1984). Chicken GnRH II ([His5,Trp7,Tyr8]-GnRH) is 
the most active of the naturally occurring GnRH peptides in stimulating gonadotropin release 
from chicken pituitary cells (Millar et al., 1986b; Chou et al., 1985) while salmon GnRH 
([Trp7,Leu8]-GnRH) is two to five times more active than chicken GnRH I (Millar et al., 
1986b). These results indicate that Trp in position seven may increase GnRH activity in the 
chicken. Lamprey GnRH I is inactive in cultured chicken pituitary cells, indicating that amino 
acids in positions 3 and 6 may be important for GnRH activity in birds (Sower et al., 1987). 
Extrapolating from LH releasing experiments, the chicken GnRH receptor appears to have a 
broader specificity than that of mammals and a relatively low affinity (Hasegawa et al., 
1984). This apparent low affinity may explain why few workers have reported receptor 
binding experiments in birds. Receptor binding assays in mammalian systems became widely 
used only after the development of radiolabeled superactive agonists (Clayton et al. 1979). 
The activities of the naturally occurring GnRHs in mammalian and chicken systems will be 
explored more thoroughly in chapter 2. 
High doses of GnRH are required for in vivo experiments in fish compared with those 
required for experiments in mammals (King and Millar, 1987). This is probably due to 
inhibitory activity of endogenous dopamine which can be counter-acted by pimozide, a 
dopamine antagonist (Peter et al., 1985; Peter, 1986). The GnRHs which occur in higher 
vertebrates were equipotent in vivo in stimulating gonadotropin release in goldfish (Peter et 
al., 1985; King and Millar, 1987; Sherw~ 1987; Horvath et al., 1986). GnRH stimulates 
secretion of growth hormone in addition to gonadotropin in goldfish. Distinct GnRH receptors 
control the secretion of these two trophic hormones (Murthy and Peter, 1994). Mammalian 
GnRH, salmon GnRH and chicken GnRH II exhibited high potency in stimulating release of 
both hormones in vitro while chicken GnRH I was an order of magnitude less potent (Habibi 
et al., 1992). The two receptors were distinguished by their responses to synthetic analogues 
of GnRH (Murthy and Peter, 1994; Habibi et al., 1992). Specific, high affinity GnRH 
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receptors have been demonstrated in goldfish (Habibi et al., 1987, 1989a, 1990) and in 
catfish, which had higher affinity for salmon GnRH than for analogues of mammalian GnRH 
which act as superagonists in mammals (De Leeuw et al., 1988; Habibi et al., 1989b). 
Differences in activity of various GnRH peptides have not been demonstrated in either 
amphibians or reptiles (Peter, 1986; King and Millar, 1987 for reviews). It is clear that the 
structural requirements for GnRH activity in non-mammalian vertebrates are different from, 
and may be less specific than in mammals. Although the non-mammalian GnRH receptors 
share the characteristic of not discriminating between the different naturally · occurring 
GnRHs, this does not necessarily mean the GnRH receptors in teleosts, amphibians and birds 
are more similar to each other than they are to mammalian GnRH receptors (Peter, 1986). 
The biologically active conformation of On.RH 
The solid phase method of peptide synthesis was developed by Merrifield in the 1960s 
(Merrifield, 1963), shortly before the structure of GnRH was first determined (Matsuo et al., 
1971). This new technology allowed rapid development of novel GnRH analogues for clinical 
and pharmaceutical applications (Karten and Rivier, 1986). Synthetic analogues of GnRH 
have also been useful as tools for investigating how GnRH interacts with its receptor. 
The entire length of the GnRH peptide is required for full GnRH activity. A series of 
peptides successively shortened form the carboxy-terminus were essentially inactive except 
for des-GlylO-GnRH which exhibited 10% potency (Rivier et al., 1973). All other fragments 
and deletion analogues of GnRH were inactive (Sandow et al., 1978; Karten and Rivier, 
1986). Since it is unlikely that all of the sidechains of this relatively large ligand are in contact 
with the receptor, the requirement of the full peptide length suggests that the amino- and 
carboxy termini interact with the receptor and that the peptide backbone plays a role in 
positioning the functional groups which interact with the receptor. 
The conformation of the GnRH molecule has been investigated by proton and 13c 
nuclear magnetic resonance and by circular dichroism (Chary et al., 1986, Deslauriers et al., 
1975, Cann et al., 1979). The NMR studies showed that GnRH is highly flexible in solution 
and they do not indicate that it has any strong conformational preferences (Chary et al., 1986; 
Deslauriers et al., 1975). The circular dichroism study showed that GnRH exists in solution as 
a mixture of structural conformers which have different sensitivities to temperature and 
solvent composition (Cann et al., 1979). In spite of its lack of defined secondary structure in 
solution, GnRH is likely to have a preferred conformation at the receptor (Deslauriers et al .• 
1975). 
The most abundant conformers of GnRH in solution are likely to be those which are 
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most stable and have the lowest free energy. One of these more abundant species could 
represent the bioactive conformation which interacts with the GnRH receptor (Morrison et al., 
1987). The computer-based techniques of molecular dynamics simulations and molecular 
modelling have been used to determine the likely conformations of GnRH. Momany (t976a) 
identified three low energy conformations of GnRH which are likely to occur in solution. All 
three of these structures "seem to be hinged at Gly6". Substitution of the achiral Gly residue 
with a bulky L-amino acid would "open the structure up" and change the conformation around 
Gly6. But the "hinge" would be stabilized by substitution of Gly6 with a D-amino acid. The 
"hinge" consisted of a modified type II ~-bend starting with Tyr in the ith position, Gly in the 
i + 1, Leu in the i + 2, and Arg in the i + 3. Comparison of the three calculated structures with 
experimental data obtained with synthetic analogues of GnRH, identified one conformer as 
the structure likely to interact with the GnRH receptor (Momany, 1976b). This structure 
indicated that the GnRH receptor might make contact with a face of the GnRH molecule 
consisting of the Arg8 sidechain, Gly10-NH2, the cis peptide of pGlul and the His2 ring. Two 
other energy minimization studies have also identified conformers with turns around Gly6 and 
Leu7 (Struthers et al., 1985; Morrison et al., 1987). Shinitzky and Fridkin (1976) built a 
model of GnRH based on a proposed interaction between the sidechains of the residues in 
positions two, five and eight. Their model also contained a bend in the middle portion of the 
molecule. Knowledge-based computer modelling, in which the sequence of GnRH_ was 
compared with protein sequences of known structure, also generated a model of the active 
GnRH conformation which contained a ~-tum (Gupta et al., 1993). In this case, however, it 
was a type III turn formed by the Trp3-Ser4-Tyr5-Gly6 residues. This model predicted that the 
surface interacting with the receptor will consist of pGlul, Glyl<>NH2 and the sidechains of 
Arg8 and Trp3. 
Experimental approaches to determining the biologically active conformation of GnRH 
have involved the introduction of conformational constraints into the GnRH molecule. 
Backbone conformational constraints limit the number of conformations available to the 
peptide and increase peptide potency by stabilizing biologically active conformers (Freidinger 
et al., 1980) or decrease potency by stabilizing inactive confonners. Substitution of D-Ala for 
Gly6 improved the activities of both agonist and antagonist analogues of GnRH, probably due 
to increased binding affinity (Monahan et al., 1973). In contrast, L-Ala6-substituted GnRH 
showed decreased potency. These data were considered to be consistent with GnRH having a 
type-II bend formed by Ser4-Tyr5-Gly6-Leu 7 when it interacts with the receptor (Monahan et 
al., 1973). However, substitution of Leu 7 with N-Me-Leu, which eliminated the possibility of 
a hydrogen bond between the N-H of Leu 7 and the C=O of Ser4, did not affect GnRH potency 
(Ling and Vale, 1975). Thus, the enhanced potency of [D-Ala6]-GnRH does not reflect 
stabilization of a ~bend incorporating a Ser4-Leu7 hydrogen bond, but it was consistent with 
a ~-tum conformation of residues five to eight, as was described by energy minimization 
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studies (Momany, 1976a). When the proposed ~-tum conformation of residues five to eight 
(Momany, 1976a) was stabilized by incorporation of a y-lactam ring at the Gly-Leu peptide 
bond, the resulting analogue was nine times more active than GnRH in vitro (Freidinger et al., 
1980). The enhanced potencies obtained with three different conformational constraints (D-
amino acids, N-Me-Leu7 and y-lactam), all of which stabilize a type-II ~-tum structure, 
provide strong evidence for the existence of this type of structure in GnRH when it binds to 
the receptor (Freidinger et al., 1980). 
Attempts were also made to constrain the active conformation of GnRH by peptide 
cyclization. A peptide in which the sidechains of residues in positions four and seven were 
covalently linked (cyclo-[Glu4,D-Ala6,0rn 7]-GnRH) was inactive (Donzel et al., 1977). This 
did not, however, disprove the hypothesis of a ~-turn at residues Ser-Tyr-Gly-Leu, because 
the linear homologue, [Gln4,D-Afa6,Qm7(Ac)]-GnRH, was also inactive. Two peptides 
cyclized through residues one and ten (cyclo-[~-Alal,D-A1a6,G1yl<>J-GnRH and cyclo-[6-
aminohexanoyll,D-Ala6,G1yl<>J-GnRH) exhibited 1% of the activity of GnRH in vivo and 
were more active than the same peptides before cyclization (Seprodi et al., 1978). Similar 
peptides, cyclo-[~-Ala 1,2-D-N al6 ,Gly 10]-GnRH, cyclo-[ y amino butyric acid 1,2-D-
Nal6 ,Gly l<>]-GnRH and cyclo-[6 amino caproic acidl,2-D-Nal6,G1yl<>]-GnRH were partial 
agonists with high affinity for the GnRH receptor (Rivier et al., 1985).· This suggests that 
some degree of peptide flexibility may be necessary for full agonist activity, or that free 
carboxy- or amino-terminal sidechains are necessary for receptor activation while not being 
necessary for high affinity binding. While peptide cyclization has not been useful in · 
determining a conformation in which GnRH activates its receptor, it has been useful in the 
design of GnRH antagonists. A bicyclic GnRH antagonist with bridges between residues four 
and ten and between residues five and eight exhibited high affinity (Kd, 0.22 nM) for the 
GnRH receptor (Rivier et al., 1992). GnRH and GnRH agonists may assume the same 
backbone conformation as this antagonist for binding to the receptor. Alternatively, since the 
binding sites for peptide agonists and antagonists are likely to be distinct, although 
overlapping (Fong and Strader, 1994), agonists may assume a different conformation at the 
receptor and agonist flexibility may be necessary for receptor activation. 
The contribution of individual amino acid residues to GnRH activity 
Many different in vivo and in vitro methods have been used to analyze the activities of 
GnRH agonists and antagonists. Early studies ut:ili7.ed in vivo assays which were relatively 
insensitive and did not distinguish changes in affinity from changes in efficacy. / n vivo test 
systems are affected by factors such as resistance of analogues to proteolytic enzymes, 
binding of analogues to plasma proteins and peptide interactions with cell membrane 
phospholipids. These factors influence the survival of test peptides in the circulation (Karten 
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and Rivier, 1986) and provide an indication of how analogues will behave when administered 
pharmacologically. However, they result in relatively indirect estimates of the interactions of 
peptides with the GnRH receptor. / n vitro assays are less subject to the pharmacokinetic 
properties of peptides and allow independent measurement of receptor binding activi_ty and 
receptor activation as monitored by LH release or inositol phosphate production. As this 
review aims to analyze the interaction of GnRH with the receptor, it will emphasize the 
results of in vitro assays where they are available. 
The amino-terminal pGlu residue was found to be important for the biological activity 
of GnRH during the original purification of the peptide (Amoss et al., 1971). Subsequently, 
most substitutions for pGlul caused complete loss of activity. Analogues with the cyclic 
(O=C)Serl (Fujino et al., 1972a), acylated Glyl (Okada et al., 1973) or D-pGlul retained 
some activity and indicated that the -CO-NHCHCO group is necessary for significant levels 
of GnRH activity (Coy et al., 1975; Sandow et al., 1978). 
The imidazole ring of His2 has a number of chemical features which make it a potential 
catalyst of receptor activation. These include its aromatic character, acid-base properties and 
capacity for hydrogen bonding (Coy et al., 1975). The acid-base and hydrogen bonding 
properties of His2 can be altered quite drastically with retention of considerable activity, as 
was demonstrated by [1-Nim-His2]-GnRH (6% potency) and [~-Pyrazoly-3-Afa2]-GnRH 
(19%) (Coy et al., 1975), but aromaticity is necessary in position two for GnRH activity. 
Substitutions with non-aromatic amino acids resulted in analogues with less than 0.1 % of the 
potency of GnRH, while [Phe2]-GnRH had 2-4% of the potency of GnRH and [Trp2]-GnRH 
40% (Coy et al., 1975; Katten and Rivier, 1986). These analogues were tested using in vivo 
assays which could not distinguish low affinity for the receptor from antagonist behaviour. 
The earliest in vitro assays of GnRH analogue activity showed that [Gly2]-GnRH was a 
partial agonist, having about 50% of the intrinsic activity of GnRH, but also inhibiting GnRH-
stimulated LH release to about 50% (Vale et al., 1972). Des-His2-GnRH was found to be a 
competitive inhibitor of GnRH and was thus the first GnRH antagonist described (Vale et al.; 
1972). Substitutions for His2, usually D-4-0-Phe or D-4-F-Phe, are characteristic of all 
highly active GnRH antagonists (Katten and Rivier, 1986; Ljungqvist et al., 1988; Haviv et 
al., 1993 for examples). The importance of the position 2 residue in antagonist design 
indicates that the aromatic sidechain or the peptide bond stereochemistry of His2 plays a role 
in activating the GnRH receptor (Vale et al., 1972). 
Replacement of Trp3 with non-aromatic amino acids resulted in almost complete loss of 
activity, while [Phe3]-GnRH and [Tyr3]-GnRH showed low activity (Coy et al., 1975; 
Sandow et al., 1978). Substitutions with the unnatural aromatic amino acids, 2-naphthyl-Ala 
and pentamethyl-Phe (Me5-Phe), resulted in analogues with about 50% potency (Sandow et 
al., 1978; Coy et al., 1974). Since Me -Phe is quite different from Trp, but resembles it in its 
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ability to form 1t-1t complexes with certain aromatic compounds, the high potency of [Mes 
Phe3]-GnRH suggested that Trp3 interacts with an electron acceptor group in the receptor. 
Replacement of the position 5 hydrogen atom, in the aro~atic nucleus of Trp3, with an 
electron-withdrawing fluorine atom resulted in an analogue, [5-F-Trp3]-GnRH, ~th only 6% 
potency. This supported the proposal that electron transfer from the Trp3 ring is important for 
GnRH activity (Coy et al., 1974, 1975). [D-Trp3]-GnRH exhibited low LB-releasing potency 
(0.13%) in vivo, and it was suggested that the altered stereochemistry prevented efficient 
binding to the receptor (Hirotsu et al., 1974; Coy et al., 1975). However, D-Trp3 was later a 
component of many high affinity GnRH antagonists (Karten and Rivier, 1986 for review). 
This indicates that D-Trp3-analogues of GnRH may bind to the receptor with high affinity, 
but that the L-stereochemistry is necessary for receptor activation. Thus, Trp3 probably also 
plays a role in activating the GnRH receptor, possibly via a 1t-1t interaction with an aromatic 
residue in the receptor. Alternatively, it may interact with an electron acceptor such as a basic 
amino acid, or an OH or NH group in the receptor. 
Analogues in Ser4 was substituted with residues which had small sidechains, Ala, Tor 
and Gln, retained activity (4 to 19% of GnRH) (Coy et al., 1975; Sandow et al., 1978), but 
larger substituents, Ser(Bul) or Leu, resulted in complete loss of activity (Sandow et al., 
1978). This suggests that there are spatial constraints in the folding of GnRH, or in the 
binding pocket of the receptor, which cannot accommodate the larger sidechains. This 
reasonably good tolerance of substitutions in position four contrasts with the 100% 
conservation of Ser4 in all of the naturally occurring GnRH structures described to date. The· 
high degree of conservation would indicate that Ser4 has an important role in GnRH activity. 
The few substitutions for Tyr5 which were tested caused only small losses of GnRH 
activity (Coy et al., 1975; Sandow et al., 1978). This tolerance at position five has been 
exploited in the development of GnRH receptor binding assays, for which Tyr5 is iodinated, 
and in attempts to decrease the histaminic response of GnRH antagonists (Roeske et al., 
1987). 
The importance of the achiral Gly6 residue lies in its ability to support the biologically 
active conformation of GnRH as discussed above. Its flexibility allows a bend in the peptide 
which is not energetically favoured by the stereochemistry of L-amino acids, but which is 
favoured by synthetic D-isomers (Momany, 1976a). D-amino acids with large sidechains can 
be incorporated in position six (Sandow et al., 1978; Karten and Rivier, 1986 for reviews). 
This indicates that there is space in the ligand binding pocket of the receptor to accommodate 
these substitutions or that their sidechains may be oriented away from the receptor. 
Most GnRH analogues with substitutions for Leu 7 retained moderate activity (Coy et 
al., 1975), although analogues with small or charged sidechains (Sandow et al., 1978) or with 
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D-Leu (Hirotsu et al., 1974) in position seven were less active while [Pro7]-GnRH was 
inactive (Sandow et al., 1978). Thus, a relatively large, uncharged residue with L-
stereochemistry is necessary in position seven for full GnRH activity. 
The position eight residue is the most variable in the naturally occurring GnRHs and the 
basic guanidyl sidechain of the Arg8 in mammalian GnRH is the determinant of the 
specificity of mammalian GnRH receptors for mammalian GnRH. Substitution with Lys 
yielded a peptide with approximately 10% of the LR-releasing activity and receptor binding 
affinity of GnRH (Shinitzky et al., 1976; Milton et al., 1983), while substitution with neutral 
Gln or hydrophobic Leu decreased LR-releasing activity and GnRH receptor binding affinity 
by two orders of magnitude (Sandow et al., 1978; Milton et al., 1983). Thus, the basic 
sidechain in position eight affects the affinity of binding of GnRH to its receptor. However, 
since position-eight substitutions had similar effects on receptor binding and LH release, Arg8 
does not appear to have a role, once the ligand is bound, in activating the receptor. Two 
hypotheses were put forward to explain the basis of the higher affinities of Arg8-containing 
GnRHs. An ionic interaction of Arg8 with one or more negatively charged residues, either an 
amino acid sidechain (Hazum, 1987) or a polysaccharide sialic acid residue (Keinan and 
Hazum, 1985), in the receptor, were proposed. The alternative proposal was that the sidechain 
of Arg8 affects the structure of the ligand, stabilizing the active conformation of GnRH by 
hydrogen bonding with the sidechains of His2 and Tyr5 (Shinitzky and Fridkin, 1976; 
Shinitzky et al., 1976; Hazum et al., 1977). Low pK values were measured for His2 and Tyr5 
in GnRH and it was suggested that the more acidic nature of these amino acid sidechains was 
due to their proximity to the cationic sidechain of Arg8 (Shinitzky and Fridkin, 1976). GnRH 
analogues with neutral substitutions, Gln (Milton et al., 1983) and co-nitro-Arg (Shinitzky et 
al., 1976), in position eight, exhibited normal, higher pK values for His2 and Tyr5, and 
extended titration ranges. These results indicate decreased interaction of the His2 and Tyr5 
sidechains with the neutral substituents in position eight. The decreased sidechain interaction 
was proposed to decrease stabilization of the bioactive conformation and thus cause the lower 
bioactivity of the neutral GnRH analogues. The model of GnRH structure derived from these 
studies (Shinitzky and Fridkin, 1976), while not described in detail, has a bend in the middle 
of the molecule which allows close apposition of the amino- and carboxy-termini. In this 
respect it is similar to models of GnRH which were based on energy minimization and 
database sequence comparison (Monahan et al., 1973; Momany, 1976a, 1976b; Struthers et 
al., 1985; Gupta et al., 1993). This thesis will address the functional importance of Arg8 in 
chapters 2 and 4. 
The rigidity imposed by Pro in pos1tton nine was expected to have important 
conformational effects (Coy et al., 1975) and the few substitutions that were tested decreased 
GnRH activity (Sandow et al., 1978). In contrast, the amino-terminal Gly-NH2 residue can be 
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altered considerably-without substantial loss of activity (Coy et al., 1975). Substitutions with 
several small alkylamides increased GnRH activity (Fujino et al., 1972b), while substitutions 
with larger amides (Fujino et al., 1972b), Ala or D-amino acids (Coy et al., 1975, Sandow et 
al., 1978) decreased activity. However, the uncharged nature of the carboxy-terminal amide is 
important for LB-releasing activity. The free acid peptide was 1000-fold less active than 
GnRH (Sievertsson et al., 1971). 
In conclusion, much of the work on analogues of GnRH has been directed at the 
development of pharmacologically active peptides which were tested in vivo, rather than at 
dissecting the functional relevance of various structural features. All residues of GnRH can be 
substituted to some degree without total loss of activity. Thus, no single residue is absolutely 
crucial to GnRH activity. The amino-terminal residues His2 and Trp3 and the -CO-NHCHCO 
group of pGlul appear to be important in activating the GnRH receptor, while the carboxy-
terminal residues Arg8, Pro9 and Glyl°NH2 are necessary for high affinity binding to the 
receptor. Gly6 allows GnRH to assume the biologically active conformation which is required 
for high affinity interaction with the receptor. 
THE GnRH RECEPfOR 
During the last two and a half decades much has been learnt about the structural 
features of GnRH which are important for its function. However, this information has been 
accumulated from experiments based largely on only one side of the receptor-ligand 
interaction, because the structure of the receptor was unknown. Information about the 
structure of the receptor is crucial for understanding how GnRH binds to the receptor, how 
the receptor is activated and how it interacts with G-proteins. Knowledge of the GnRH 
receptor ligand binding site will facilitate the development of improved analogues for clinical 
applications and in time the development of non-peptide GnRH analogues is expected to 
revolutionize male and female contraception. 
GnRH has its most important function in the pituitary. In mammals, the pituitary GnRH 
receptor is located exclusively on the gonadotrope cells which secrete LH and FSH (Naor, 
1990). GnRH receptors have also been reported to occur in several non-pituitary tissues 
including rat and human gonads (Hazum and Keinan, 1984; Iwashita and Catt, 1985; Hazum 
and N~ 1982; Latouche et al., 1989) and human placenta (Iwashita et al., 1986) and in 
human neoplasms (Miller et al., 1985; Eidne et al., 1985; Clayton, 1989; Kakar et al., 1994). 
Since the physiological significance of the extra-:pituitary actions of GnRH are unclear (Naor, 
1990) this review will concentrate on the pituitary GnRH receptor. 
Several attempts were made to purify the GnRH receptor by conventional biochemical 
methods. Jansem De Almeida Catanho et al. (1983) solubilized bovine pituitary membranes 
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in Triton X-100 and used concanavalin A affinity chromatography to partially purify an 
approximately 60kD GnRH binding protein. Hazum et al. (1986) purified two GnRH binding 
proteins with Mr5 of 59 and 57 kD. They solubilized rat pituitary membranes in a zwitterionic 
detergent and isolated the receptor with an avidin affinity column to which [biotinyl-D-Lys6J-
GnRH was coupled. The bovine GnRH receptor was also purified by this procedure and was 
used to produce antibodies to the GnRH receptor (Hazum et al., 1987). However, neither 
group published amino acid sequences of their GnRH binding proteins. Christiansen and 
Houen (1994) purified a 60kD protein from bovine pituitaries using similar methodology 
(solubilization in Triton X-114 followed by affinity chromatography on a GnRH-agarose 
column), but their partial amino acid sequence shows no homology with the deduced amino 
acid sequence of the recently cloned bovine GnRH receptor (Kakar et al., 1993). Purification 
of GnRH binding proteins by affinity chromatography is discussed in more detail in chapter 3. 
Primary structure: the GnRH receptor is a rhodopsin-type G-protein coupled receptor 
The structure of the GnRH receptor was first elucidated when it was cloned from cDNA 
of the aT3 mouse gonadotrope cell line. A polymerase chain reaction (PCR)-based strategy 
was combined with hybrid-arrest screening in Xenopus oocytes (Tsutsumi et al., 1992). The 
sequence was confirmed by Reinhart et al. (1992) and Perrin et al. (1993) and was used to 
clone GnRH receptors from human (Kakar et al., 1992; Chi et al., 1993), rat (Kaiser et al., 
1992; Eidne et al., 1992; Perrin et al., 1993), sheep (Brooks et al., 1993; Illing et al., 1993), 
bovine (Kakar et al., 1993) and porcine (Weesner and Matteri, 1994)' pituitaries. The 
sequences of the cloned GnRH receptors exhibit high homology with greater than 80% amino 
acid identity between any two sequences. 
The cloned GnRH receptors have many of the characteristic features of G-protein 
coupled receptors (GPCRs). They consist of a single amino acid chain with an extracellular 
amino-terminal domain which does not have a terminal signal sequence, seven hydrophobic 
putative membrane-spanning segments and a cytosolic carboxy terminus. There are three 
major families of seven transmembrane GPCRs in mammals: the rhodopsin family which 
comprises at least 300 members, the secretin receptor family and the metabotropic glutamate 
receptor family (Schwartz, 1994; Baldwin, 1994). The GnRH receptors contain the distinctive 
sequence patterns characteristic of the rhodopsin group (fig. 1.3) (Baldwin, 1993). The high 
degree of conservation of particular amino acid residues amongst the rhodopsin family of 
GPCRs suggests that this family of receptors may have a common structure. The conserved 
residues probably have important roles in maintaining receptor structure (Findlay et al., 
1993). 
The rat and mouse GnRH receptors contain three N-glycosylation consensus sequences 
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(Asn-X-Ser/Thr). Mutagenesis studies have shown that two of these sites, the Asn4 and Asn18 
residues, are glycosylated when the mouse receptor is transiently expressed in COS-1 cells, 
while Asnl02 is not (Davidson et al., 1995). However, the GnRH receptor in native pituitary 
membranes migrates with a lower apparent Mr than does the wildtype receptor expressed in 
C0SM6 cells (Perrin et al., 1993). This suggests that only one residue is glycosylated in vivo. 
As the Asn4 site is not conserved in other species of GnRH receptor, it is possible that only 
Asn18 is glycosylated in the pituitary. While the polysaccharide moieties do not affect the 
affinity of ligand binding to the receptor, they do seem to affect receptor stability as mutations 
of Asn4 or Asn18 decreased receptor expression (Davidson et al., 1995). These results are 
consistent with an early study in which treatment of cultured pituitary cells with tunicamycin, 
an inhibitor of N-glycosylation, decreased the number of GnRH receptors without affecting 
binding affinity (Schvarz and Hazum, 1985) and with a subsequent study which showed that 
treatment of solubilized GnRH receptors with wheat germ agglutinin or with neuraminidase, 
which cleaves terminal sialic acid residues, did not affect ligand binding affinity (Hazum, 
1987). 
Unusual features of the GnRH receptor sequence 
The cloned GnRH receptors also have some unique features. They are nearly the 
smallest of the GPCRs, with only 327 amino acids, in the case of the rat and mouse receptors, 
and 328 amino acids in the other species, which contain an insertion in the second 
extracellular loop. They lack the polar cytoplasmic C-terminal domain which is involved in 
the short term homologous desensitization of many GPCRs by receptor kinases (Hausdorf et 
al., 1990; Palczewski and Benovic, 1991) and indeed, GnRH receptor-mediated inositol 
phosphate production does not exhibit homologous desensitization after stimulation with 
GnRH for more than 90 minutes (Davidson et al., 1994a). Thus, the well described 
desensitization of physiological responses to GnRH administration (Cayton, 1989) must 
depend on other mechanisms, such as receptor internalization and intracellular responses 
distal to the generation of inositol phosphates (Davidson et al., 1994a). Honda et al. (1995) 
have recently shown that another Gq-coupled receptor (platelet-activating factor receptor) is 
desensitized via down-regulation of the IP3 receptor which regulates cytosolic ea2+ levels. 
This mechanism might also account for desensitization of responses to GnRH. 
The putative first cytoplasmic loop of the GnRH receptor is unusually long (f sutsumi et 
al., 1992). This long loop may substitute for the cytoplasmic C-terminal domain in functions, 
such as receptor internali7.ation, which require the cytoplasmic C-terminal segment in other 
GPCRs (Nussenzvieg et al., 1993; Thomas et al., 1995). Alternatively, it may support one of 
the unusual functional characteristics of the GnRH receptor such as ligand-induced up-
regulation of the receptor (Clayton, 1982; Loumaye and Catt, 1983) or receptor activation via 
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Figure 1.3 A two-dimensional diagram of the mouse GnRH receptor. Highly conserved 
key residues characteristic of the rhodopsin group of GPCRs are indicated by bold circles: 
TMI, N53; TMII, L80, L83; TMTII, Cl14, 1135_S-x-D-Rl39; 1MIV, w164, 5167, p173; TMV, 
p219_x-x-P222, M226, :(233; TMVI, K266, p275_x-x-C-W-x-P-Y282; TMVII, p310, N314, p319_ 
x-x-Y322. Substitutions in positions of residues highly conserved in other GPCRs are 
indicated by squares: N87, 5140, 0318. Other residues mentioned in the text are marked by 
diamond symbols: N4, N18, N102, K121, 098 andE301. 
dimerization (Tsutsumi et al., 1992; Conn et al., 1982; Gregory et al., 1982; Hazum and 
Keinan, 1985). 
Another unusual feature of the cytosolic smface of the GnRH receptor is Ser140 in the 
position of the highly conserved Tyr (Y) residue of the "DRY" motif (Probst et al., 1992) at 
the cytosolic end of transmembrane helix III (fig. 1.3). The Asp/Glu and Arg residues of this 
motif have been implicated in the coupling of some GPCRs to their G-Proteins (Baldwin, 
1994; Fahmy and Sakmar, 1993). It is possible ·that this coupling is modulated by 
phosphorylation of the Tyr residue and that substitution with Ser allows regulation by a 
serine-threonine kinase instead of by a tyrosine kinase. However; ·mutation of Ser140 to Ala 
had no obvious effect on GnRH receptor function (Davidson et al., 1994b). 
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Secondary and tertiary structure, allosteric regulation and G-protein coupling 
The three-dimensional structure of GPCRs is unknown. Their association with the 
membrane makes them difficult to isolate and manipulate without denaturation. The shell of 
detergent which is necessary to maintain receptor conformation impedes formation of the 
crystals needed for diffraction studies (Findlay and Eliopoulos, 1990). However, the 
structures of six other integral membrane proteins have been reported (Kuhlbrandt, 1995). 
These structures provide some information about the intramembrane domains of membrane 
proteins (Findlay and Eliopoulos 1990). Intramembrane regions are largely a-helical. The 
helices span the membrane and are connected by 'loops' which are exposed to the polar 
environment and located at the surface of the membrane bilayer or extending into the aqueous 
phase (Findlay and Eliopoulos 1990). The a-helices are not absolutely regular. Distortions 
may be caused by Pro residues (Findlay and Eliopoulos 1990; Baldwin, 1993) and by 
stretches of hydrophilic residues (Findlay and Eliopoulos 1990). 
Like the GPCRs, bacteriorhodopsin, one of the integral membrane proteins for which 
the structure has been reported, contains seven stretches of hydrophobic amino acids, which 
span the membrane. Bacteriorhodopsin is also similar to rhodopsin in that it responds to light 
through isomerization of covalently bound retinal (Baldwin, 1993; Soppa, 1994). Because of 
these similarities, the structure of bacteriorhodopsin has been used as a basis for several 
models of GPCRs (Findlay and Eliopoulos, 1990; Hibert et al., 1991; Trump-Kallmeyer et 
al., 1992; Zhang and Weinstein, 1993; reviewed by Schwartz, 1994). However, unlike 
rhodopsin, bacteriorhodopsin does not activate a G-protein and it has no sequence similarity 
with any of the GPCRs (Soppa, 1994; Schwartz, 1994). A projection map of rhodopsin, 
recently determined by electron crystallography of two-dimensional crystals, shows that the 
structure of rhodopsin clearly differs from that of bacteriorhodopsin. The resolution of this 
map (9A) is too low to allow identification of specific helices. However, compared with that 
of bacteriorhodopsin, the projection map of rhodopsin is less elongated and slightly wider and 
the helices are tilted differently. The map shows four helices nearly perpendicular to the 
membrane and three helices which are more tilted (Schertler et al., 1993). As the general 
arrangement of helices is similar in rhodopsin and bacteriorhodopsin, conclusions from 
models based on bacteriorhodopsin as to which residues face the centre of the molecule, 
should be valid However, conclusions regarding specific interactions such as ligand binding 
and receptor activation would be unreliable as these depend on detailed knowledge of the 
relative positions of amino acids contained in different helices (Baldwin, 1994). 
The conservation of particular amino acids within the hydrophobic regions of the 
rhodopsin GPCRs implies conserved structural and functional roles for these residues and 
implies that the proteins of the family share a common structure and mechanism of activation. 
Roles of the conserved residues may include maintaining the integrity of helix packing or 
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providing a framework for the binding pocket (Findlay et al., 1993). They may also relay 
conformational changes associated with receptor activation. A probable arrangement of the 
helices of the GPCRs has been proposed, taking into consideration the sites of the most 
conserved residues in 105 unique receptor sequences; the sites where variability is restricted; 
sites which contain polar residues; sites where differences in sequence occur between closely 
related receptors and the rhodopsin projection map (Baldwin, 1993). Highly conserved 
residues, because of their proposed role in maintaining molecular structure, are expected to 
face other helices or the inside of the helical bundle (Donnelly et al., 1989). Conserved 
proline residues sometimes cause kinks in the helices and thus may be on any face of the 
helix. Baldwin's analysis shows that helices I, II, IV, V and VI have clearly defined 
hydrophilic and lipophilic surfaces while helices ill and VII show less segregation. 
Hydrophilic surfaces are likely to face towards the interior of the molecule while lipophilic 
surf aces are likely to be in contact with the membrane lipids. Helix ill has very little 
lipophilic area. This helix is thus likely to be somewhat buried within the molecule and less 
exposed to the membrane lipid. The helices are probably arranged anticlockwise as viewed 
from the extracellular side of the membrane (Baldwin, 1993; Schwartz, 1994). 
The conserved Cys residue at the extracellular end of the third transmembrane helix in · 
the GnRH receptor probably forms a disulphide bridge with one of the Cys residues in the 
second extracellular loop. This second Cys residue is highly conserved in occurrence but not 
in position (Schwartz, 1994). The disulphide bridge probably stabilizes the active 
conformation of GPCRs (Baldwin, 1994). The importance of a disulphide bridge in the GnRH 
receptor was shown by an early experiment in which treatment with the reducing agent 
dithiothreitol decreased the affinity of GnRH agonist binding (Keinan and Hazum, 1985). 
Several models of specific receptors have recently been based on the proposed structure 
of rhodopsin (Findlay et al., 1993; Zhou et al., 1994). However, only a few studies have 
investigated specific contact points between the helices (Schwartz, 1994). Mutation of the 
Asn312 residue in helix VII of the ~2 adrenergic receptor to the Phe found in the a.2 receptor 
caused complete loss of function. Replacement of the first two helices of the mutant ~2 
receptor with the corresponding a.i receptor sequence restored activity. Similarly, replacing 
the equivalent Phe412 residue of the a.i adrenergic receptor with the Asn found in the ~2 
receptor caused a loss of agonist binding which could be rescued by helix I of the ~2 receptor. 
This is compatible with a model of these receptors in which there is interaction of the 
Phe/Asn residue in helix VII with helix I (Suryanarayana et al., 1992). Similar 'rescue' 
experiments have also indicated contact between helix I and helix VII of the muscarinic 
receptors (Pittel and Wess, 1993). A mutant Asp residue in helix II of rhodopsin from a 
patient with stationary night blindness was found to substitute for the counterion (usually Glu 
in helix III) of the Schiff base in helix VII (Rao et al., 1994). Thus the sidechains of these 
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three residues (the usual Gly in helix II, Glu in helix ill and Lys in helix VII) project into the 
same space within the rhodopsin molecule. This finding supports the anticlockwise 
arrangement of the transmembrane helices (Schwartz, 1994). 
The GnRH receptor has also been used as a model for the identification of interhelical 
interactions. Two of the highly conserved residues, Asp in helix II and Asn in helix VII (fig. 
1.3), are not conserved in the GnRH receptor. In fact they appear to be interchanged, with 
Asn87 in the conserved position in helix II and Asp318 in the helix VII position. This 
suggested that the GnRH receptor might be a natural reciprocal mutant compared with the 
other GPCRs and that the interchange might indicate that the two residues interact with each 
other. Mutation of Asn87 in helix II to Asp abolished receptor function. A second mutation, 
recreating the arrangement found in other GPCRs (Asp87 Asn318), regenerated ligand binding. 
This restoration of binding by the reciprocal mutation shows that the sidechains of two 
residues in helices II and VII have complimentary roles in maintaining the structure of the 
receptor and occupy the same microenvironment within the receptor (Zhou et al., 1994). 
Subsequent work has shown that all mutations of Asn87 (Asp, Ala and Gln) without a 
compensatory mutation at position 318 abolish receptor function. A hydrogen bond which 
may form between Asn87 and Asp318 is not important for proper receptor structure as 
substitution of Asp318 with Ala (which does not form hydrogen bonds) had a minimal effect 
on receptor structure as monitored by ligand binding (W. Zhou, H. Weinstein, C. Flanagan, R. 
P. Millar and S. C. Sealfon, in preparation). This also shows that Asn87 must participate in an 
interaction with a residue, other than Asp318, which is important for receptor structure. 
Substitution of Asp318 with Glu decreases receptor expression by 90% (W. Zhou, H. 
Weinstein, C. Flanagan, R. P. Millar and S. C. Sealfon, in preparation). This probably shows 
that the intramolecular environment is confined and cannot easily accommodate an extra 
methylene group. 
All mutations of Asp318 result in decreased inositol phosphate production in response to 
GnRH. When the receptor binding levels are taken into account, the rank order of uncoupling 
is Afa318 > Asp87 Asn318 (double mutant) > Asn318 > Glu318 (W. Zhou, H. Weinstein, C. 
Flanagan, R. P. Millar and S. C. Sealfon, in preparation). This rank order indicates that both 
the presumed negative charge and hydrogen bonding capacity of Asp318 are important for 
coupling of agonist binding to intracellular signal transduction. 
The helix II Asp has been widely studied. In many receptors, mutation of the conserved 
Asp disrupts receptor-G-protein interactions. This uncoupling is characterized by a decrease 
in agonist binding affinity, loss of the allosteric effect of GTP, which decreases agonist 
binding affinity, and decreased activation of G-proteins (Chung et al., 1988, ~ adrenergic 
receptor; Ceresa and Limbird, 1994, ai adrenergic receptor; Quintana et al., 1993, LH/CG 
receptor). The uncoupling of GnRH receptors mutated at Asp318, in helix VII, suggests that 
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the functional role of the helix II Asp in other GPCRs might indeed be located at the helix VII 
Asp in the GnRH receptor. Alternatively, both residues may function in coupling the agonist 
binding signal to G-protein activation. One study has analyzed the importance of the 
conserved Asn residue in helix VII. It appears to have a role in maintaining the structure of 
the human 5HT lA serotonin receptor. Coupling to intracellular signal transduction was not 
investigated (Chanda et al., 1993). 
The conserved helix II Asp also mediates the regulation of agonist binding by sodium 
ions in many GPCRs (Horstman et al., 1990; Ceresa and Limbird, 1994; Kong et al., 1993; 
Quintana et al., 1993). However, an exploratory experiment in our laboratory suggested that 
this function of the helix II Asp has not been transferred to the helix VII Asp of the GnRH 
receptor. Cations modulate GnRH receptor agonist binding (Hazum, 1981; Loumaye et al., 
1984; Keinan and Hazum, 1985; Wormald et al., 1985; Hazum, 1987) and antagonist binding 
(Hazum, 1981; Loumaye et al., 1984). Monovalent cations Na+, K+ and Cs+ inhibit GnRH 
agonist binding with similar IC5os in the range 10 to 25 mM while divalent cations are more 
potent inhibitors with IC5os ranging from 0.025 mM for Cu2+ to 1 mM for Ca2+ (Keinan and 
Hazum, 1985; Hazum, 1987). It has been suggested that cations bind to carboxylic groups 
within the ligand binding site of the GnRH receptor (Keinan and Hazum, 1985; Hazum, 
1987). However, examination of the inhibition cUIVes shows that some cations do not 
completely inhibit agonist binding, while others (Cu2+ and Mn2+) exhibit very steep 
inhibition curves. These steep curves indicate a complex mechanism of inhibition rather than 
simple competitive inhibition. Thus, while it is likely that cations interact with one or more 
acidic amino acid residues as proposed, the residues are unlikely to be directly involved in 
ligand binding. The effect of cations on receptor affinity is probably an allosteric effect which 
causes a change in receptor conformation. 
The intracellular loops of the GPCRs, particularly the third intracellular loop, mediate 
coupling to G-proteins (Dohlman et al., 1991; Conklin and Bourne, 1993). Peptides 
corresponding to short segments of the intracellular loops are sufficient to bind and activate 
G-proteins. Therefore, in the absence of agonist, the inactive receptor must be able to 
constrain or shield such peptide segments from productive interaction with G-proteins 
(Samama et al., 1993). Thus it has been proposed that receptors exist in an equilibrium 
between two conformations R and R *. Agonist binding shifts this equilibrium towards R *, 
which can be regarded as the active confonnation. The R * conformation exhibits high affinity 
for agonist ligands, and, according to this theory, is the only form which can bind the G-
protein (Samama et al., 1993). The existence of at least two conformations of the ~ 
adrenergic receptor are supported by the increased agonist binding affinity of a constitutively 
active mutant receptor (Samama et al., 1993) and by the increased basal activity when the 
wildtype receptor is overexpressed (Bond et al., 1995). Addition of GTP (or a non-
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hydrolyzable GTP analogue which activates G-proteins) destabilizes the ternary complex of 
hormone-receptor-G-protein and allows the receptor to return to the R conformation which 
has low affinity for agonists (De Lean et al., 1980). 
The ligand binding domain 
Receptor activation is initiated by binding of an agonist ligand. Consequently, the 
conformational changes associated with receptor activation must have their origin in the 
ligand binding pocket (Findlay and Eliopoulos, 1990). Because of the spectroscopic 
properties of its tethered ligand, the ligand binding site of rhodopsin is the most widely 
studied. Toe bound retinal is located approximately 22 A deep within the membrane bilayer. 
When the structural similarities between the cloned !3-adrenergic receptor and rhodopsin were 
noted, it was suggested that the conserved transmembrane domains of these receptors might 
provide a common site for agonist binding (Strader et al., 1994). 
The significant chemical features of adrenalin and noradrenalin, the natural ligands of 
the !3-adrenergic receptors, consist of a basic amine group, a stereoselective f3-hydroxyl group 
and a catechol ring of which both hydroxyl groups are necessary for full activity. Specific 
residues in the f3-adrenergic receptor have been identified as contact points for each of these 
functional groups. Asp113 in transmembrane helix III of the f3-adrenergic ,receptor has been 
shown to form a salt bridge with the amine group, while two Ser residues in helix V form 
hydrogen bonds with the catechol hydroxyl groups. A Phe residue in helix VI has been 
implicated in binding to the catechol ring and it has been proposed that a Ser residue in helix 
IV interacts with the !3-hydroxyl group (Strader et al., 1994 for review). It has been proposed 
that the different amino acid residues which occur in equivalent positions in other related 
receptors participate in equivalent interactions with their ligands (Hibert et al., 1991). 
Sequence alignment shows that all receptors that bind biogenic amines have an Asp residue in 
helix III in the position corresponding to the Asp113 of the f3-adrenergic receptor. 
Mutagenesis studies have shown that the helix ill Asp plays a critical role in ligand binding 
by a.-i-adrenergic, muscarinic and histamine receptors (Strader et al., 1994 for review). 
The GnRH receptor has a basic residue, Lysl21, in helix ill at the position analogous to 
the Asp113 of the f3-adrenergic receptor. Substitution of Lysl21 with an uncharged Gin 
decreased the binding affinity of agonist analogues but did not affect antagonist binding 
affinity (Zhou et al., 1995). This indicates that Lysl21 may interact with agonist ligands, but 
not with antagonists. GnRH antagonists differ from agonists chiefly in their amino-termini, 
where the pGlu-His-Trp sequence of GnRH is substituted with aromatic D-amino acids. Thus, 
an amino-terminal residue of GnRH may interact with Lys121 of the receptor. The interaction 
clearly does not involve a salt bridge as there are no negative charges in GnRH. The 
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electropositive Lys121 sidechain may form a hydrogen bond with the electron-dense aromatic 
rings of the His2 or Trp3 residues of GnRH, the imino group of His2 (Zhou et al., 1995), or a 
carbonyl group in the peptide backbone. In an early attempt to determine the nature of GnRH 
receptor residues involved in GnRH binding using chemical modification of pi_tuitary 
membranes, the N-hydroxysuccinimide ester of acetic acid which modifies free amino groups 
did not affect GnRH binding (Keinan and Hazum, 1985). The combination of this information 
with the mutagenesis results suggests that the Lys121 residue is relatively inaccessible to the 
solvent or that its environment within the receptor decreases its reactivity. 
GnRH is a considerably larger ligand than are the biogenic amines. As a consequence, 
the binding pocket of the GnRH receptor probably extends beyond the transmembrane 
domain. If there is a common origin of the conformational changes associated with activation 
of the rhodopsin family of receptors, it is likely to be a site accessed by all ligands. Such a site 
would be contained in the membrane-spanning helical bundle. Thus, it can be expected that 
the amino-terminal portion of the GnRH ligand, which is responsible for receptor activation, 
is the part that interacts with the transmembrane portion of the ligand binding pocket It has 
recently been suggested that the activating end of another peptide ligand (substance P) 
interacts with a residue in the transmembrane domain of its receptor (Huang et al., 1994; 
Strader et al., 1994). 
Peptide ligands are more complex than the biogenic amines. Their larger size means 
that they have many more functional groups, both in the amino acid sidechains and in the 
peptide backbone, which can potentially interact with specific receptor residues. The ligand 
binding pockets of peptide receptors need to be larger than those of the biogenic amines in 
order to accommodate the larger size of their ligands. Consequently, in addition to residues in 
the transmembrane domains (Yokota et al., 1992; Mauzy et al., 1992; Huang et al., 1994; 
Strader et al., 1994; Krystek et al., 1994; Zhou et al., 1995), both the extracellular amino-
terminal segments and the extracellular loops of peptide receptors have been implicated in 
binding of diverse peptide ligands (Fong et al., 1992a; Walker et al., 1994; DeMartino et al., 
1994; Hjorth et al., 1994). Indeed, the ligand binding sites for the large glycoprotein 
hormones, LH, FSH and TSH, are largely contained within the extracellular amino-terminal 
domains of their receptors (Segaloff and Ascoli, 1993; Dallas et al., 1994). It has, however, 
been suggested that after binding to the amino-terminal domain of its receptor, LH is 
positioned in contact with the transmembrane domain in order to initiate receptor activation 
(Ji and Ji, 1991a, 1991b; Ji et al., 1993). This implies that the origin of receptor activation lies 
in the transmembrane domain and that the mechanism of activation might be the same as in 
receptors which bind small ligands. 
There is also evidence that shows that the extracellular segments of the GnRH receptor 
are involved in ligand binding. Deletion of part of the amino-terminal segment of the receptor 
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abolishes ligand binding and GnRH-stimulated inositol phosphate production (S. C. Sealfon, 
unpublished results). Chemical modification of the GnRH receptor in pituitary membranes 
indicated that at least one and possibly two carboxyl groups are involved in GnRH binding 
(Hazum and Keinan, 1985). The carboxyl groups were attributed to Glu or Asp residues or to 
polysaccharide sialic acid residues (Keinan and Hazum, 1985; Schvartz and Hazum, 1985; 
Hazum, 1987). Mutagenesis of the glycosylation consensus sequences in the mouse GnRH 
receptor has shown that polysaccharides do not affect ligand binding affinity (Davidson et al., 
1995). However, two acidic amino acid residues which affect the binding of GnRH have been 
identified in the first and third extracellular loops of the mouse GnRH receptor. These 
residues, Asp98 and Glu301, will be discussed in chapter 4. 
Treatment of the GnRH receptor in rat pituitary membranes with 2-methoxy-5-
nitrobenzyl bromide, which modifies the indole ring of Trp residues, decreased subsequent 
binding of a GnRH agonist This suggests that a Trp residue has an important role in ligand 
binding (Keinan and Hazum, 1985). Similarly, treatment with p-diazobenzenesulphonic acid 
or iodoacetamide indicated that a Tyr residue, but not a His, participates in ligand binding 
(Keinan and Hazum, 1985). The specific Trp and Tyr residues have yet to be identified in the 
cloned GnRH receptors. 
GnRH and many other peptides are highly flexible and exist as an equilibrium mix of 
conformers in solution (Karten and Rivier, 1986). The multiplicity of peptide conformations 
adds to the complexity of ligand binding interactions in peptide receptors. The complexity 
was revealed by studies utilizing chimaeric receptors, consisting of segments from different 
receptor subtypes. Subtypes are closely related receptors which recognize a single ligand or a 
family of structurally similar peptides. For example, the neurokinin receptor subtypes, NKl, 
NK2 and NK3, bind the neurokinin peptides substance P, neurokinin A and neurokinin B, 
which have the common Carboxy-terminus, Phe-Xaa-Gly-Leu-Met-NH2• However, each 
receptor subtype recognizes the peptides with a different rank order of affinity. Chimaeric 
receptors, consisting of segments from different receptor subtypes, have been used to locate 
general regions involved in ligand-binding domains, prior to identification of the specific 
residues concerned by point mutations (Schwartz et al., 1994; Strader et al., 1994 for 
reviews). It would be expected that conserved residues in the peptide ligands would interact 
with receptor residues which are conserved across all subtypes. Similarly, variant ligand 
residues would be expected to interact with variant receptor residues. However, experience 
with the neurokinin receptors has shown that this is not necessarily true and it has been 
suggested that this probably relates to peptide co~ormation (Fong et al., 1992a; Strader et al., 
1994; Huang et al., 1994). Exchange of four variant residues in the amino-terminal and first 
extracellular loop regions of the NKl receptor for the amino acids which occur in equivalent 
positions in the NK3 receptor did not affect subtype selectivity and decreased receptor affinity 
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for all peptide ligands (Fong et al., 1992a). Clearly the divergent receptor residues do not 
affect only interactions with divergent residues in the ligands. Exchanging residues in the 
second and third extracellular loops of the NKl receptor with equivalent residues of the NK3 
receptor increased affinity of the mutant NKl receptor for neurokinin B, the preferred _ligand 
of the NK3 receptor. However, the exchange did not decrease affinity of the mutant' NKl 
receptor for its own ligand, substance P (Fong et al., 1992a). Similarly, chimaeras of the NKl 
and NK2 receptors showed that the epitope which determines high affinity binding of 
substance P is located in the region extending from transmembrane helix II to the second 
extracellular loop of the NKl receptor. However, chimaeras incorporating the equivalent 
region of the NK2 receptor did not exhibit high affinity for neurokinin A (Yokota et al., 
1992). Thus the residues which determine the ligand selectivity of receptor subtypes are 
located at different positions in different receptors. Similarly, residues located at different 
sites in the ET A and ETB endothelin receptors have been shown to determine endothelin 
subtype selectivity (Mauzy et al., 1992; Krystek et al., 1992). It is now clear that the positions 
of ligand contact sites vary between subtypes of peptide receptors. Within a single receptor, 
both conserved and divergent residues appear to interact with conserved residues which occur 
in all peptide ligands. Divergent residues located in different regions of the different receptors 
determine subtype selectivity (Strader et al., 1994). Probably, each receptor subtype 
recognizes a different peptide conformation (Fong et al., 1992a). Different peptide 
conformations would position some of the ligand functional groups (both conserved and 
divergent) differently within the ligand binding pocket and cause them to interact with 
residues in different positions in the receptor sequences. 
Several different forms of GnRH have been identified in various vertebrate species (see 
structures of naturally occurring GnRHs). The differences in their amino acid sequences are 
similar to the differences found in the sequences of the neurokinin peptides. This suggests 
that, in the absence of well described subtypes of the GnRH receptor, the relationship of the 
mammalian GnRH receptors to any one of the non-mammalian receptors may be similar to 
that found between subtypes of receptors for peptides such as the neurokinins. If this is true, 
amino acid sequence homology between mammalian and non-mammalian GnRH receptors 
should be about 60 to 80% in the transmembrane helices (Strader et al., 1994). In addition, 
the non-mammalian receptors probably show selectivity for peptide conformations different 
from that preferred by the mammalian receptors. As discussed earlier in this chapter, the 
mammalian GnRH receptor appears to recognize GnRH in a conformation containing a ~-II 
bend. Constraining this conformation enhances binding to the mammalian GnRH receptor, 
but is much less effective in increasing interaction with the chicken pituitary GnRH receptor 
(Millar et al., 1986b; chapter 2). This indicates that the chicken GnRH receptor does not bind 
GnRH in the same conformation as do the mammalian GnRH receptors. The chicken GnRH 
receptor will be discussed in more detail in chapter 2. 
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In addition to the ability of receptors to recognize particular conformations of peptide 
ligands, it is possible that receptors cause the ligands to change conformation subsequent to 
binding. It has been proposed that binding of the glycopeptide ligand, C5a, to the amino-
terminal segment of its receptor is followed by a change in the conformation of the ligand 
which exposes the carboxy-tenninal portion of the ligand. This allows subsequent interaction 
of the exposed carboxy-tenninus with the transmembrane domain of the receptor (DeMartino 
et al., 1994). We have also proposed that the conformation of GnRH is modified by 
interaction with its receptor (Flanagan et al., 1994; discussed in chapter 4). 
The antagonist binding domain 
It is becoming clear from studies with many GPCRs that agonist and antagonist ligands 
do not necessarily occupy the same ligand binding domain even though antagonists appear to 
be competitive inhibitors of agonist binding (Fong et al., 1992a, 1992b; Gether et al., 1993; 
Huang et al., 1994; Strader et al., 1994). It has been proposed that the competitive behavior 
arises from a volume exclusion effect in which agonist and antagonist binding pockets 
overlap in space, although agonist and antagonist ligands interact with different receptor 
residues (Fong et al., 1992a; Huang et al., 1994; Strader et al., 1994). It has also been 
observed that some (non-peptide) antagonists are not simple competitive inhibitors of agonist 
binding (Huang et al., 1994; Rosenkulde et al., 1994), and it has been proposed that they 
inhibit agonist access by an allosteric mechanism (Rosenkulde et al., 1994). 
The GnRH receptor also appears to have different binding domains for agonist and 
antagonist ligands. Mutation of the Lysl21 residue affects binding of agonists but not of 
antagonists (Zhou et al., 1995). Thus, Lysl21 may be an agonist contact site, but it is clearly 
not an antagonist binding site. Even before the cloning of the GnRH receptor allowed site-
directed mutagenesis, there was evidence that the GnRH receptor binding sites for agonists 
and antagonists differed. Pretreatment of pituitary membranes with proteolytic enzymes, 
trypsin and chymotrypsin, decreased subsequent binding of labelled antagonist more than it 
did binding of labelled agonist (Hazum, 1981). This suggests that the agonist binding site was 
less exposed to the enzymes. The agonist binding site may, thus, be more buried within the 
membrane domain of the receptor. A different proteolytic approach was more recently used to 
compare the binding sites of photoactive agonist and antagonist analogues of GnRH 
(Janovick et al., 1993). Radioiodinated photoactive agonist and antagonist peptides were 
covalently attached to the GnRH receptor in pituitary membranes. Both of the resulting 
labelled receptor-ligand complexes migrated as broad bands with a Mr range of 46-60 K on 
SOS-PAGE. The broadness of the bands is due to heterologous glycosylation of the receptor. 
After treatment of the receptor-ligand complexes with trypsin, the agonist label was still 
attached to the glycosylated amino-terminal fragment of the receptor which migrated with a 
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33-48 K range of Mr In contrast, the antagonist label migrated with the dye front of the gel, 
showing that it was bound to a much smaller fragment of receptor which was not glycosylated 
(Janovick et al., 1993). At the least, this shows that the environment of the photoactive group 
attached to a D-Lys in position 6 of the ligands is different for agonists and antagonists~ Thus, 
two quite different approaches, mutagenesis of Lys121 and proteolytic cleavage of the 
receptor, show that the binding sites for GnRH agonists and antagonists differ. 
Although it has been shown that most vertebrate species have more than one form of 
GnRH (King and Millar, 1992) and multiple receptor subtypes have been demonstrated 
(Murthy and Peter, 1994; Murthy et al., 1994), the high sequence homologies and similar 
pharmacological behavior of the receptors cloned to date indicate that they all belong to a 
single subtype. Consequently, it has not been possible to use GnRH receptor subtype 
chimaeras to investigate ligand binding domains. However, in some receptor systems, 
chimaeras of the same receptor subtype from different species have been used to investigate 
binding of non-peptide antagonists (Fong et al., 1992b; Sachais et al., 1993; Jensen et al., 
1993). Non-peptide ligands have not yet been described for the GnRH receptor, but species 
differences have been reported in the recognition of peptide GnRH antagonists by human and 
rat receptors (Wormald et al., 1985). Chimaeras of mammalian GnRH receptors may thus 
provide a useful tool for investigating the GnRH antagonist binding domain. 
In other peptide receptor systems, non-peptide antagonists have provided useful 
pharmacological tools. Their binding sites are different from the binding sites of both agonists 
and peptide antagonists. Consequently, they exhibit different sensitivities to receptor 
mutagenesis and allow analysis of the ligand binding properties of mutant receptors which 
have low affinities for peptide ligands (Fong et al., 1992a; Gether et al., 1993). Development 
of non-peptide ligands (whether agonist or antagonist) for the GnRH receptor will facilitate 
studies of the receptor. The cloning of the GnRH receptor will allow establishment of systems 
to screen lead compounds for development of non-peptide analogues of GnRH. In turn the 
growing understanding of the receptor ligand binding domain will optimize the development 
of new GnRH analogues. 
Development of non-peptide analogues of GnRH will revolutionize the 
pharmacological and prophylactic applications of GnRH analogues. Resistance of the new 
analogues, because of their non-peptide nature, to digestive enzymes will allow them to be 
administered orally. The new ease of administration is anticipated to make non-peptide GnRH 
analogues the basis of a new generation of non-steroidal oral contraceptives for both men and 
women. 
CHAPTER2 
CHARACTERIZATION OF STRUCTURAL REQUIREMENTS FOR GnRH 
RECEPTOR BINDING AND GONADOTROPIN RELEASE USING CHIMAERAS OF 
VARIANT GnRH FORMS 
SUMMARY 
Eleven variant forms of GnRH have now been identified in various animal species. The 
most frequently substituted residues are those in positions 5, 7 and 8. Chimaeric analogues of 
4 vertebrate forms of GnRH were synthesized in order to study the functional significance of 
the most common substitutions. Peptides were tested for their ability to stimulate release of 
LH and FSH in cultured sheep pituitary cells and LH in cultured chicken pituitary cells. 
Binding affinities for the GnRH receptors in sheep and rat pituitary cell membranes were also 
measured. Arginine was required in position 8 for high GnRH activity in mammalian systems, 
but analogues with neutral substitutions in position 8 were more potent in chicken pituitary 
cells. Toe chicken GnRH receptor appears to be less stringent than the mammalian receptors 
in its recognition of peptide conformation. Histidine in position 5 decreased LH releasing 
potency in chicken cells, but slightly increased receptor binding affinity in rat and sheep 
membranes. Tryptophan in position 7 had minimal effect on GnRH activity in mammals, but 
increased LH release in chicken cells. Some substitutions affected receptor binding affinity 
and receptor activation differently in sheep pituitaries. Peptides with histidine in position 5 
had relatively high receptor binding potency compared with their LH releasing potency, while 
peptides with Trp7,Tyr8 substitutions exhibited relatively high gonadotropin releasing 
potencies and lower receptor binding affinities. Rat GnRH receptors exhibited higher affinity 
for analogues with tryptophan in position 7 than did sheep GnRH receptors. 
INTRODUCTION 
Although early studies suggested that the structure of GnRH was conserved throughout 
the vertebrates (Jeffcoate et al., 1974), eleven different forms of GnRH have now been 
identified in the various animal species (see chapter 1, Structures of naturally occurring 
GnRHs). During the 500 million years of evolution separating the most primitive vertebrates, 
lampreys, from mammals, the GnRH residues in positions 5, 7 and 8 have been most subject 
to substitution. 
It is well known that mammalian GnRH receptors require the Arg8 residue found in 
mammalian GnRH (Sandow et al., 1978). However, studies with chicken GnRH II 
([His5,Trp7,Tyr8]-GnRH) showed that it was more active than chicken GnRH I ([Gln8]-
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GnRH) in rat and sheep pituitaries as well as in chicken pituitaries (Miyamoto et al., 1984; 
Millar et al., 1986b). This indicated that analogues of GnRH with Hiss and/or Trp7 
substitutions might have increased gonadotropin releasing activity and high affinity for the 
GnRH receptor. Such analogues could form the basis of a new series of GnRH agonists and 
antagonists containing only naturally occurring L-amino acids. 
In addition, a previous study reported that chicken GnRH II was more potent in 
stimulating FSH release than in stimulating LH release in cultured chicken pituitary cells 
(Millar et al., 1986b). This suggested that chicken GnRH II might be the contentious specific 
FSH releasing peptide (reviewed in Mizunuma et al., 1983). 
In this study, chimaeras of naturally occurring GnRH mutants were synthesized in order 
to investigate the functional significance of the position 5, 7 and 8 substitutions. Chimaeras 
were based on mammalian GnRH, chicken GnRH I ([Gln8]-GnRH), salmon GnRH 
([Trp7,Leu8]-GnRH) and chicken GnRH II ([His5,Trp7,Tyr8]-GnRH) because these structures 
were known at the time. Receptor binding and gonadotropin releasing properties of the 
chimaeras were studied in two mammalian systems (sheep and rat) and one non-mammalian 
system (chicken). 
MATERIALS AND METHODS 
Peptides 
GnRH analogues [Trp7,Leu8]-GnRH and [Leu8]-GnRH were gifts from Dr. R. Roeske. 
[D-Trp6,01n8]-GnRH was synthesized by R. P. Millar. Other peptides were synthesized by R. 
Milton. Mammalian GnRH, lamprey GnRH I and [D-Trp6]-GnRH were synthesized manually 
and the rest were synthesized on a Beckman System 990 peptide synthesizer using 
conventional solid phase methodology on p-methylbenzhydrylamine-1 % divinylbenzene-
styrene copolymer resin. Cleavage of the peptide-amide from the resin and concomitant 
deprotection were perf onned in redistilled hydrogen fluoride containing 1 % anisole. Peptides 
were purified by preparative C18 reversed phase HPLC to greater than 96% purity (integrated 
area under the main peak vs the total integrated area recorded at 210 nm). Peptides were used 
as trifluoroacetic acid salts except for mammalian GnRH and [D-Trp6.]-GnRH which were 
converted to acetate form by chromatography on DEAE cellulose (Whatman DE52). Amino 
acid compositions were determined by gas phase hydrolysis in 6M HQ (Waters Pico-Tag 
system) followed by o-phthalaldehyde derivatization. Compositions were consistent with the 
predicted peptide sequences. Concentrations of peptides used in biological tests were 
calculated using the peptide contents determined by amino acid analysis. 
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Culture of chicken pituitary cells and stimulation of Ul release 
Anterior pituitaries were dissected from chicken heads (Golden Grove Poultry Co., 
Cape Town) which had been washed with disinfectant (Hibitane, 0.5% chlorhexidene 
gluconate in 80% methanol) and kept on ice for less than 2 h. Pituitaries were collected into 
HEPES-buffered (20 mM, pH 7.4) Dulbecco's Modified Eagle's Medium (DMEM) (Gibco, 
Grand Island, NY) to prevent desiccation. They were then minced with a scalpel blade and 
digested for 1 h at 37° C with continuous slow stirring in collagenase solution [0.9% w/v 
collagenase (155 U/mg, Worthington Biochemical Corp, Freehold, NJ), and 18 mg/1 
deoxyribonuclease (Miles laboratories, Elkhart, IN), in HEPES-BSA buffer (25mM HEPES, 
pH 7.2, 137mM NaCl, 5mM KCl, 0.7mM Na2HP04, 0.36mM CaC12, lOmM glucose and 
lOg/1 BSA, fatty acid free, Pentex fraction V, Miles Laboratories)]. Cell clumps were broken 
up by passage through a pipette at 10 min intervals. The cell suspension was centrifuged 
twice at 500 g for 5 min and the pellet resuspended each time in buffer A (140mM NaCl, 
4mM KCl, 1.4mM Na2HP04, 8.3mM glucose, 20mM HEPES, pH 7.4, and 6mg/l phenol red) 
to which 0.5mM EDTA and 0.3% (w/v) BSA were added. The cell suspension was then 
filtered through nylon gauze prior to dilution in DMEM containing 10% foetal calf serum 
(Gibco), penicillin (60 mg/1), streptomycin (100 mg/1), neomycin (100 mg/1) and 
amphotericin B (20 mg/1) and dispensed into 6-well tissue culture plates (Falcon, Oxnard, 
CA) at a density of 1.3 pituitary equivalents per well. One pituitary equivalent amounts to 
about 5 x 105 cells. Cells were cultured at 37° C in 5% CO2 for 24 h, after which the medium 
was replaced with amphotericin B-free medium and culture was continued for a further 24 h. 
Prior to stimulation, cells were washed twice with buffer A containing lmM CaC12 and 0.1 % 
(w/v) BSA and preincubated for two periods of 5 min in the same buffer. Triplicate 
stimulations were performed for 30 min at 37° C with peptides dissolved in the same buffer. 
Medium was collected, centrifuged to remove any loose cells, and stored at -20° C until 
radioimmunassay for chicken LH. Mammalian GnRH was included in all bioassays as a 
reference standard for comparing the activity of GnRH analogues. 
Culture of sheep pituitary cells and stimulation of gonadotropin release 
The gonadotropin releasing activities of synthetic GnRH analogues were assessed in 
cultured sheep pituitary cells using a previously described method (Millar and King, 1983a; 
Millar et al., 1986b). Briefly, anterior pituitaries were dissected from sheep heads within 30 
min of slaughter, minced, and digested in collagenase solution as described for chicken 
pituitaries. The cells were resuspended in Eagle's Minimum Essential Medium with Hank's 
salts (MEM) (Gibco, Paisley, Scotland) containing 10% foetal calf serum and antibiotics, and 
cultured (105-1()6 cells/well) at 37° C in 5% CO2 for 4 or 5 days with a medium change after 
3 days. Cells were washed twice in MEM containing 10% foetal calf serum and 4 times with 
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serum-free MEM. Peptide stimulations were performed for 2h in 1ml serum-free MEM at 37° 
C in 5% CO2. 0.9 ml of medium was collected into tubes containing 0.1 ml of HEPES-BSA 
buffer, centrifuged and stored (-20° C) until radioimmunoassay for sheep LH and FSH. 
Gonadotropin radioimmunoassays 
Purified sheep LH (LER-1056-C2, a gift from L. E. Reichert) was iodinated using 
chloramine T, and separated from free radioidide on a cellulose CF 11 (Whatman Inc., 
Clifton, NJ) column. Sheep LH radioimmunassays (RIA) were performed as previously 
described (Millar and Aehnelt, 1977) using unlabeled sheep LH (NIH-LH-S18) to generate 
the standard curve and antiserum GDN 15 (a gift from G. D. Niswender, Colorado State 
University) which had been raised against sheep LH. The sheep FSH RIA was performed 
according to instructions using oFSH-RPl as standard, 125I-oFSH-I-1 (radioiodinated as for 
LH) and anti-oFSH-1 antiserum (1:160 000 final dilution) which were supplied by S. Raiti 
(National Hormone and Pituitary Program, NIDDK). Chicken LH was measured as 
previously described (Pollet et al., 1972) using antiserum 16/6 and 125I-(Sharp PRC AEI-1). 
For all 3 assays antiserum-bound label was precipitated using second antibody coupled to 
cellulose (Sac-Cel RD70, Wellcome Reagents Limited, Beckenham, England). All of the 
samples from each stimulation experiment were included in the same assay. Interasssay 
coefficients of variation were 13.7 % for chicken LH, 4.6% for sheep LH and 8.3% for sheep 
FSH. 
GnRH receptor binding assays 
Competitive binding of GnRH peptides to rat pituitary cell membranes was investigated 
as previously described (Millar and King, 1983a; Millar et al., 1986b). In addition a sheep 
pituitary GnRH receptor binding assay was developed for this study. Anterior pituitaries from 
adult male rats (Long-Evans) or castrated adult male sheep were homogenized in ice-cold 
lOmM tris-HCl buffer containing lOmM tris, pH 7 .4, lmM dithiothreitol, lmM EDTA and 
0.1 % (w/v) BSA. The rat pituitary homogenate was centrifuged for 30 min at 15 000 x g and 
4° C and the resulting pellet was resuspended in tris-HCl buffer. The sheep pituitary 
homogenate was centrifuged first at 100 x g (5 min, 4° C), to remove a component which 
exhibited high non-specific binding, and the resulting supernatant was recentrifuged at 3 500 
x g for 10 min at 4° C. The pellet was resuspended in tris-HO buffer. The resuspended 
membranes (0.16 rat or 0.05 sheep pituitary equivalents per tube) were incubated (90 min on 
ice) with 125I-[D-Afa6,N-MeLeu7,Pro9NHEt]-GnRH (60 000 cpm, iodinated by the 
chloramine T method, specific activity 1000 Ci/g) and increasing concentrations of test 
peptides in a final volume of 0.5 ml. The incubation was terminated by addition of 3 ml of 
phosphate-buffered saline containing 1 % (w/v) BSA (PBS-BSA) and immediate filtration, 
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under vacuum, through glass-fibre filters (GF/C, Whatman), presoaked in PBS-BSA. Filters 
were washed 3 times with 3 ml PBS-BSA and the retained radioactivity was counted in a 
gamma counter. Non-specific binding (2% in rat, 26% in sheep) was determined in the 
presence of 1Q-6M [D-Afa6,N-MeLeu7,Pro9NHEt]-GnRH and subtracted from all samples. 
Data analysis 
EC50 values (peptide concentrations required for half-maximal stimulation of 
gonadotropin release) and IC5os (peptide concentrations required for half-maximal inhibition 
of 125J-[D-Afa6,N-MeLeu 7,Pro9NHEt]-GnRH binding) were determined using four-parametre 
nonlinear curve-fitting (ALLFI1) (DeLean et al., 1978), forcing curves to share minimum and 
maximum values. Potencies were calculated relative to the EC5os and IC5os obtained with 
mammalian GnRH. All values presented are the means of at least 2 experiments performed in 
triplicate. 
RESULTS 
Mammalian systems 
Toe non-mammalian GnRHs exhibited relatively low potencies in stimulating release of 
LH and FSH from cultured sheep pituitary cells (table 2.1, fig. 2.lA). They also exhibited low 
binding affinity for both sheep and rat GnRH receptors (table 2.1, figs. 2.10, 2.2A). The 
common feature of these peptides is the substitution of a neutral residue for the basic Arg8 of 
mammalian GnRH. The low gonadotropin releasing potencies and binding affinities of the 
position 8-substituted analogues [Leu8]-GnRH and [Tyr8]-GnRH (table 2.1, figs. 2.lB, 2.lE, 
2.2B, 2.3) and the relatively low potencies of all chimaeras containing neutral residues in 
position 8 (table 2.1, fig 2.3) confinned the importance of Arg8 for GnRH activity in 
mammals. 
The IC50 for GnRH in the sheep receptor binding assay was more than an order of magnitude 
higher than the ECsos for LH and FSH release. This is consistent with the existence of a 
considerable receptor reserve in pituitary gonadotropes. Because of the differences in the 
absolute values of EC5os and ICsos, potencies were calculated relative to mammalian GnRH 
to allow comparison of the different assays. The relative binding affinities of the non-
mammalian GnRHs correlated broadly with their relative LH and FSH releasing activities. 
However, their gonadotropin releasing potencies were an order of magnitude higher than their 
receptor binding potencies (table 2.1, figs. 2.4, 2.lA, 2.10). Higher gonadotropin releasing 
potency than receptor binding potency was a characteristic of all peptides with neutral 
residues in position 8 (figs. 2.4, 2.1, table 2.1). 
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Figure 2.1 Stimulation of LH release and competition for binding of 12s1.[D-Afa6,N. 
MeLeu 7,Pro9NHEt]-GnRH by GnRH analogues in sheep gonadotropes. LH release, left 
panels, GnRH receptor binding, right panels. Symbols are identified in the key in fig. 2.2 (facing page). 
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Figure 2.2 GnRH analogue competition for binding of 12SJ.[D-AJa6,N. 
MeLeu 7,Pro9NHEt]-GnRH in rat pituitary membranes. 
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Figure 2.3 Comparison of 
LH releasing potencies of 
vertebrate GnRHs and 
chimaeras in sheep and 
chicken pituitary cells. 
Figure 2.4 Relationship between the 
receptor binding potencies and LH 
releasing potencies of GnRH peptides 
in sheep. Numbers correspond to the 
peptides in table 2.1, (-) indicates a 1: 1 
relationship, (--) indicates an order of 
magnitude displacement from a 1:1 
relationship. 
Figure 2.5 Relationship between ICsoS 
of GnRH analogues in rat and sheep 
pituitary membranes. Numbers 
correspond to the peptides in table 2.1, 
(-) indicates a 1:1 relationship, (--) 
indicates an order of magnitude 
displacement from a 1: 1 relationship. 
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Chicken GnRH II ([His5,Trp7,Tyr8]-GnRH) was the most active of the non-mammalian 
GnRHs in the sheep and rat test systems. Chimaeric peptides were synthesized to test the 
hypothesis that the His5 or Trp 7 substitutions might account for the higher potency of chicken 
GnRH II compared with peptides containing substitutions only in position 8. Incorporation of 
His5 into GnRH slightly increased binding affinity for sheep and rat GnRH receptors and 
slightly decreased sheep gonadotropin releasing activity (table 2.1, figs 2.lE, 2.2B, 2.lB). 
Trp 7 alone or in combination with Hiss (peptides 9 and 10 in table 2.1) had minimal effects 
on GnRH receptor binding affinity or gonadotropin release. In combination with Tyr8, His5 
increased binding affinity (5-fold) without affecting gonadotropin release (peptide 11 
compared with peptide 7 in table 2.1). In contrast, incorporation of Trp 7 enhanced the 
gonadotropin releasing activity of [Tyr8]-GnRH without affecting binding affinity (peptides 
12 and 7 in table 2.1). Thus, His5 seems to account for the relatively high binding affinity of 
chicken GnRH II, while Trp7 seems to account for its higher biological activity. 
Comparison of the LH releasing potencies and receptor binding potencies of the GnRH 
analogues in the sheep pituitary (fig. 2.4) shows that peptides containing a His5 substitution 
had higher binding potency than releasing potency (peptides 8 and 16). Conversely, peptides 
with the highest ratio of releasing potency to binding potency contained Trp 7,Tyr8 
substitutions (peptides 12 and 19). 
D-Trp6 incorporation markedly enhanced the gonadotropin releasing acttv1ttes and 
receptor binding affinities of mammalian GnRH, chicken GnRH I and [His5]-GnRH (peptides 
14, 15 and 16 compared with peptides 1, 2, and 8) in the mammalian systems. However, it 
was much less effective in the presence of Trp in position 7 (table 2.2, figs. 2.1, 2.2). 
The was no difference in potency for release of LH compared with FSH with any of the 
peptides tested (table 2.1). 
Comparison of the results obtained in the receptor binding assays performed with sheep 
and rat pituitary membranes (fig. 2.5) shows that, while there is a general correlation of the 
affinities measured in both systems, some peptides exhibit distinctly different affinities for the 
two receptors. Peptides 3, 4, 12, 19 and 20 (table 2.1) exhibit more than 10-fold lower affinity 
for the sheep receptor than for the rat receptor. Common features of these peptides are Trp in 
position 7 and a hydrophobic residue (Tyr or Leu) in position 8. 
Chicken LH release 
Non-mammalian GnRHs were more potent than mammalian GnRH in stimulating release of 
LH from cultured chicken pituitary cells, except for lamprey GnRH I which was inactive (fig. 
2.6A). As was anticipated from this result and previous studies (Miyamoto et al., 1984; Millar 
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POTENCY RELATIVE TO PARENT COMPOUND 
GnRH LH FSH receptor binding LH 
# analogue sheep sheep sheep rat chicken 
14 D-Trp6 26.7 25.0 25.9 47.1 5.3 
15 D-Trp6,Gln8 37.1 14.2 27.0 38.9 
16 His5,0-Trp6 8.5 14.7 14.5 34.0 35.9 
17 D-Trp6,Trp7 2.3 1.5 2.1 3.6 0.53 
18 His5,0-Trp6,Trp7 1.1 1.5 10.2 
19 D-Trp6,Trp7,Tyr8 2.5 1.4 4.5 9.6 0.57 
20 His5,0-Trp6,Trp7,Tyr8 1.7 2.3 2.7 6.5 0.84 
Table 2.2 Effect of D-Trp6 incorporation on gonadotropin releasing and receptor 
binding potencies of GnRH analogues 
et al., 1986b), GnRH analogues with substitutions in position 8 showed high activity in 
stimulating LH release from chicken pituitary cells (fig. 2.6B, table 2.1). 
As was the case in the mammalian systems. chicken GnRH II ([His5,Trp7,Tyr8]-GnRH) 
was more potent than analogues with substitutions only in position 8 (table 2.1, figs. 2.6A, 
2.6B). Analysis of the contribution of His5 to the higher potency of chicken GnRH II, showed 
that His5 does not increase LH releasing potency, but rather decreases it. [His5]-GnRH was 
IO-fold less active than GnRH, while incorporation of His5 decreased the activities of [Trp7].:. 
GnRH (peptide 10 compared with peptide 9), [Tyr8]-GnRH (peptide 11 compared with 
peptide 7) and [Trp7,Tyr8]-GnRH (peptide 4 compared with peptide 12) (table 2.1, figs. 2.3, 
2.6). 
In contrast, incorporation of Trp7 enhanced release of chicken LH (table 2.1, figs. 2.3, 
2.6). [Trp7]-GnRH exhibited a potency of 5.9, while [His5,Trp7]-GnRH was more potent than 
[His5]-GnRH and [Trp7,Tyr8]-GnRH was the most potent peptide tested in the cultured 
chicken pituitary cells (table 2.1, figs. 2.3, 2.6). 
Incorporation of D-Trp6 increased chicken LH releasing activities of peptides that did 
not contain Trp 7 (table 2.2, fig. 2.6). It also completely reversed the decreases in activity 
caused by incorporation of His in position 5 (table 2.2, fig. 2.6). 
Comparison of the EC50s for LH release in chicken and sheep pituitary cells shows that 
the EC5o-5 were generally lower in the sheep system (table 2.1). The EC50 for mammalian 
GnRH was an order of magnitude lower in the sheep than in the chicken and it was lower than 
all but one of the EC5o-5 measured in the chicken pituitary cells. 
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Figure 2.6 Stimulation of LH release by GnRH analogues in chicken gonadotropes. 
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Comparison of the EC5os for LH release in chicken and sheep pituitary cells shows that 
the EC5os were generally lower in the sheep system (table 2.1). The EC50 for mammalian 
GnRH was an order of magnitude lower in the sheep than in the chicken and it was lower than 
all but one of the EC5os measured in the chicken pituitary cells. 
Comparison of potencies for LH release in the two systems (fig. 2.3) shows that 
peptides containing a hydrophobic residue in position 8 have increased potency in the 
chicken, while the same peptides have decreased potency in sheep cells. The presence of His 
in position 5 markedly decreases potency in chicken cells, but has much less effect in sheep 
cells. Trp 7 causes increased potency in chicken cells, but does not affect potency in sheep 
cells. 
DISCUSSION 
Lamprey GnRH I exhibited low potency in stimulating gonadotropin release from both 
mammalian and chicken pituitary cells, consistent with a previous report (Sower et al., 1987). 
Lamprey GnRH I is the most divergent of the non-mammalian GnRHs, containing more 
substitutions than occur in GnRHs from higher vertebrates. The differences in lamprey GnRH 
structure may reflect divergent evolution since the lampreys, which constitute part of the most 
ancient class of vertebrates, separated from the other vertebrates about 500 million years ago. 
The differences in GnRH structure are probably accompanied by differences in GnRH 
receptor structure. 
The other vertebrate GnRHs exhibited high activity in stimulating LH release from 
chicken pituitary cells, but all except mammalian GnRH had low potencies in sheep and rat 
pituitaries, consistent with previous reports (Millar and King, 1983a; Hasegawa et al., 1983; 
Millar et al., 1986b). The common structural feature of these non-mammalian GnRHs is the 
substitution of Arg8 with neutral amino acids and it has been suggested that this is responsible 
for the low affinities of these peptides for mammalian GnRH receptors (Milton et al., 1983). 
The low receptor binding affinities and gonadotropin releasing potencies of the position 8-
substituted analogues [Leu8]-GnRH and [Tyr8]-GnRH supports the importance of the basic 
Arg8 residue in mammals. Other chimaeras with neutral residues in position 8, [His5,Tyr8]-
GnRH and [Trp7,Tyr8]-GnRH, also exhibited relatively low activities in the mammalian test 
systems. In contrast, the position 8-substituted GnRH analogues all had high potency in 
stimulating release of chicken lli. These results support earlier suggesions that although 
mammalian GnRH receptors require Arg in pos~tion 8, the avian receptors are less specific, 
binding analogues with neutral or basic residues in position 8 (Hasegawa et al., 1984; Millar 
and King, 1987, 1988). Fish GnRH receptors are also relatively non-specific with respect to 
amino acid residues position 8. Mammalian GnRH, salmon GnRH and chicken GnRH II all 
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have high gonadotropin releasing potency in goldfish (Habibi et al., 1992). Thus, vertebrates 
in which the naturally occurring GnRH contains a neutral residue in position 8 appear to be 
tolerant of neutral or basic amino acid substitutions in position 8. In contrast, mammals, in 
evolving an Arg8-containing GnRH, appear also to have evolved a receptor which reqµires a 
basic residue in position 8. 
The positive charge of Arg8 in mammalian GnRH may interact with a negatively 
charged residue in the mammalian receptor (Hasegawa et al., 1984; Keinan and Hazum, 
1985; Hazum, 1987). The identification of a negatively charged Glu residue which detemiines 
the specificity of the mouse GnRH receptor in recognizing mammalian GnRH will be 
discussed in chapter 4. Arg8 has also been proposed to have a role in stabilizing the active 
conformation of GnRH. The sidechain of Arg8 appears to interact with the sidechains of the 
His2 and Tyr5 residues in mammalian GnRH (Shinitzky and Fridkin, 1976). Neutral amino 
acid substituents in position 8 interact less with the sidechains of His2 and Tyr5 and therefore 
are probably less able to stabilize the active peptide conformation (Shinitzky et al., 1976; 
Milton et al., 1983). The decreased stabilization of a biologically active conformation of the 
peptide may account for the lower activity, in mammalian systems, of GnRH analogues with 
neutral residues in position 8. In contrast, since the chicken GnRH receptor does not require 
an Arg in position 8, it appears to be less stringent in its recognition of peptide conformation 
or it may require a different conformation from that required by mammalian receptors. 
The importance of peptide conformation for interaction with mammalian GnRH 
receptors was confirmed by the effect of incorporating D-Trp in position 6 of GnRH. 
Substitution of Gly6 with a D-amino acid stabilizes a !3-tum conformation of the residues, 
Tyr5-Gly6-Leu7-Arg8, which forms an important component of the active conformation of 
GnRH (Momany, 1976a, b). In this study, incorporation of D-Trp in position 6 of mammalian 
GnRH increased receptor binding affmity and gonadotropin releasing potency more than 20-
fold, in agreement with previous studies in the rat (Millar and King, 1983b). D-Trp6 
incorporation also increased the potencies of [Gln8]-GnRH and [His5]-GnRH by an order of 
magnitude (table 2.2). However, D-Trp6 incorporation induced only small increases in the 
activities of peptides which contained Trp in position 7 (table 2.2). This may be a 
consequence of steric hindrance caused by the close proximity of 2 bulky sidechains (D-
Trp6, Trp 7) in these peptides. Alternatively, it may be a consequence of the hydrophobicity of 
the peptides (indicated by the high retention times of peptides 17, 18, 19 and 20 on reversed 
phase HPLC, table 2.1). It has been reported that increasing hydrophobicity of GnRH 
analogues is associated with increasing biological _ potency in vivo up to an optimum 
hydrophobicity, after which activity declines (Nestor et al., 1984). In this light, it is 
interesting to note that incorporation of a charged D-amino acid, D-Arg, in position 6 
increased the activity of the hydrophobic chicken GnRH II ([His5,Trp7,Tyr8]-GnRH) 9-fold 
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(Millar et al., 1986b), while in the current study incorporation of the hydrophobic D-Trp6 
increased its activity only 2-fold. 
D-Trp6 incorporation had much less effect in chicken pituitary cells. It resulted in small 
increases or decreases in LH releasing potency for most peptides (table 2.2). These findings 
are in agreement with earlier obseivations that substitutions of D-amino acids for Gly6 give 
rise to only small increases in potency in the chicken (Hasegawa et al., 1984; Millar et al., 
1986b). These results indicate that the chicken GnRH receptor is less stringent than the 
mammalian receptor in its requirement of a particular peptide conformation or that ·it requires 
a different peptide conformation from that stabilized by D-amino acids in position 6. 
Incorporation of D-Trp6 did, however, reverse the decrease in activity caused by His5, as it 
increased the potencies of the inactive His5-containing peptides by an order of magnitude 
(table 2.2). This suggests that the low LH releasing potency in the chicken which results from 
incorporation of His5 is caused by an effect on peptide conformation which can be reversed 
by a D-amino acid in position 6. 
As previously reported, chicken GnRH II was more potent than chicken GnRH I in 
stimulating LH release from both chicken and mammalian pituitary cells (Millar et al., 
1986b). This obsetvation suggested the possibility that substitution of His5 and Trp7 into 
GnRH, while retaining the important Arg8, might produce GnRH analogues, consisting 
entirely of natural L-amino acids, with activities equal to or higher than mammalian GnRH 
(Folkers et al., 1986; Millar et al., 1986b). These substitutions had minimal effect on GnRH 
activity and result in peptides ([His5]-GnRH, [Trp7]-GnRH and [His5,Trp7]-GnRH) with 
receptor binding affmities and gonadotropin releasing potencies similar to mammalian GnRH 
in mammalian test systems. These results are in agreement with an in vivo study of the same 
analogues in rats (Folkers et al., 1986). These are the first analogues of GnRH made up 
entirely of natural amino acids to exhibit activity as high as GnRH itself (Folkers et al., 1986). 
These results do not explain why chicken GnRH II has higher GnRH activity than [Tyr8]-
GnRH. However, incorporation of His5 into [Tyr8]-GnRH increased receptor binding affmity, 
while Trp 7 increased the gonadotropin releasing activity of [Tyr8]-GnRH. This suggests that 
some kind of interaction amongst the sidechains of the 3 residues accounts for the higher 
activity of chicken GnRH II. 
In contrast to the mammalian systems, substitutions in positions 5 and 7 had marked 
effects in the chicken. Incorporation of His5 caused a decline in LH releasing activity (up to 
20-fold in the case of [His5,Trp7]-GnRH compared with [Trp7]-GnRH) in chicken cells. We 
have not been able to develop a reliable chicken GnRH receptor binding assay, apparently due 
to the lack of an analogue with sufficiently high affmity for use as a tracer. In the absence of a 
receptor binding assay, it is not possible to tell whether the His5-induced decrease in LH 
releasing potency is accompanied by a similar decrease in receptor binding affinity or by 
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increased binding affinity as was the case for the sheep pituitary. If receptor binding affinity 
is not decreased, incorporation of His5 might provide a starting point for design of antagonists 
for the chicken GnRH receptor, since GnRH antagonists designed for mammalian receptors 
have very low affinity for the chicken receptor (Jacobs et al., 1995). The increased chicken 
LH releasing potency of analogues with Trp in position 7, indicates that the high activity of 
chicken GnRH II in chicken cells is due to the incorporation of this residue. 
Using full dose-response curves, no peptide was found to exhibit enhanced FSH 
releasing potency compared with LH release. Thus, this work in cultured sheep pituitary cells 
does not support a previous observation in vivo in rats that [His5]-GnRH caused preferential 
FSH release (Folkers et al., 1986). 
The EC50 for stimulation of sheep LH release by GnRH was 20-fold lower than the 
IC50 for GnRH in the sheep receptor binding assay. This difference indicates the presence of 
spare receptors and suggests that occupancy of about one twentieth of the receptors by GnRH 
would be sufficient to stimulate a full LH response (Taylor and Insel, 1990). The EC50 for 
mammalian GnRH in the chicken bioassay was similar to the IC50 in the sheep receptor 
binding assay. This may indicate either that the chicken pituitary cells have a minimum of 
spare receptors, or that the chicken GnRH receptor has low affinity for mammalian GnRH 
(Hasegawa et al., 1984). 
The calculation of potencies relative to GnRH allows comparison of results obtained in 
the stimulation and binding assays in spite of the differences in peptide concentrations 
required for half-maximal responses. Comparison of the potencies obtained in the sheep LH 
release and receptor binding assays (fig. 2.4) shows that analogues containing His5 in 
combination with Arg8 ([His5]-GnRH and [His5 ,D-Trp6]-GnRH) have high receptor binding 
potency relative to their LH releasing potency. In the absence of spare receptors, these 
peptides might act as partial agonists, stimulating less than maximum LH release at 
concentrations where all receptors are occupied. They may thus provide useful tools for the 
study of recombinant GnRH receptors. Some peptides exhibit the opposite characteristic, 
namely higher LH releasing potency than binding potency. These peptides contain neutral 
substitutions in position 8. It would appear from these results, that the neutral GnRH 
analogues, once bound, are better able to activate the GnRH receptor. This suggests that 
mammals, in evolving a charged ligand, may have evolved a high affinity ligand binding 
interaction at the expense of receptor activation. Such a system might conceivably allow a 
similar range of gonadotropin release in response to stimulation by lower levels of GnRH. 
Alternatively, it is possible that the neutral peptides stimulate gonadotropin release through a 
second receptor which is not detected in the receptor binding assay. 
Differences in the structural requirements of the chicken and mammalian receptors for 
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GnRH were anticipated. However, this study has also demonstrated a difference in the 
requirements of rat and sheep receptors. Comparison of IC5~ obtained in the sheep and rat 
receptor binding assays (fig. 2.5), shows that the sheep receptor has lower affinity (higher 
IC50s) for analogues which contain Trp in position 7 in combination with a hydrophobic 
residue in position 8. Species differences in ligand structural requirements between mammals 
have previously been demonstrated for an antagonist where human and rat pituitaries were 
compared (Wormald et al., 1985). 
In conclusion, this study has used chimaeric analogues of four vertebrate forms of 
GnRH to study the functional significance of amino acid substitutions in positions 5, 7 and 8. 
Arg8 is required for GnRH activity in mammals, while analogues with neutral amino acids in 
position 8 are more active in chicken pituitary cells. This result, combined with the 
differential consequences of incorporating a conformational constraint in the form of D-Trp6, 
supports earlier conclusions that the chicken and mammalian GnRH receptors differ in their 
recognition of ligand conformation. Incorporation of His in position 5 decreased LH releasing 
potency in chicken cells, but slightly increased affinity for mammalian GnRH receptors. Trp 
in position 7 increases GnRH activity in the chicken, but has minimal effect in mammals. No 
peptide could be identified as a preferential FSH releasing hormone, but substitution of some 
residues had differential consequences for receptor binding affinity and receptor activation. In 
addition to the expected difference between mammals and chickens, a species difference in 
peptide structural requirements between sheep and rats has been shown. 
CHAPTER3 
DEVELOPMENT OF METHODS FOR PURIFICATION OF MEMBRANE-
ASSOCIA TED GONADOTROPIN RELEASING HORMONE BINDING PROTEINS 
SUMMARY 
This study describes the development of a protocol for use in purification of the GnRH 
receptor from sheep pituitary membranes. Several detergents were tested for their ability to 
solubilize GnRH binding activity. The zwitterionic detergent, CHAPS, gave the best recovery 
of binding activity in the soluble fraction. Solubilized membranes were applied to affinity 
columns prepared with a range of GnRH analogues. Only columns prepared with two high 
affinity analogues, [D-Lys6,Pro9-NHEt]-GnRH and antagonist 26, retained more than 50% of 
the applied GnRH binding activity. NaCl concentrations up to 0.5M did not promote 
dissociation of GnRH receptor prebound to labelled GnRH agonist In contrast, low pH did 
promote dissociation of preformed receptor-ligand complexes. Thus, after application of 
solubilized membranes, columns were washed with a gradient of sodium chloride up to 0.4M 
and GnRH binding activity was eluted from the columns using an acidic buffer. This protocol 
eluted GnRH binding activity from the agonist affinity column, but not from the column 
prepared with antagonist 26. The [D-Lys6,Pro9-NHEt]-GnRH affinity column was therefore 
used for the subsequent purification. Sodium dodecyl sulfate polyacrylamide gel 
electrophoresis analysis of the acid-eluted fraction revealed a major protein band with a 
molecular weight of 67 kD. Amino acid sequence analysis of the protein showed that it is 
different from the cloned GnRH receptor, but homologous with a GnRH binding protein 
recently purified from bovine pituitary. This protein may have a function which is modulated 
by binding of GnRH, GnRH fragments or GnRH-related peptides. 
INTRODUCTION 
Since the determination of the structure of GnRH, much has been learnt about the 
structural features of the GnRH molecule which are important for its function. However, the 
accumulation of this information has depended largely on experiments designed around only 
one side of the receptor-ligand interaction, because the structure of the receptor was not 
known. Information about the structure of the receptor, thus, became crucial for further 
understanding of how GnRH interacts with its receptor. 
Several previous attempts have been made to purify the GnRH receptor by conventional 
biochemical methods. Solubilization of bovine pituitary membranes in Triton X 100, followed 
by concanavalin A affinity chromatography resulted in partial purification of a 60kD GnRH 
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binding protein (Jansem De Almeida Catanho et al., 1983). Two GnRH binding proteins were 
purified from rat pituitaries. Membranes were solubilized in a zwitterionic detergent and the 
receptor was isolated on [biotinyl-D-Lys6]-GnRH coupled to an avidin affinity column 
(Hazum et al., 1986). GnRH receptor antibodies were prepared using a bovine receptor 
preparation purified by the same protocol (Hazum et al., 1987). However, neither group 
reported amino acid sequences of their GnRH binding proteins. We used these previously 
described methods as a basis for the development of a protocol for the purification of the 
GnRH receptor from sheep pituitaries, anticipating that even a short segment of . the amino 
acid sequence could be used in strategies to clone the GnRH receptor. 
Although only a single GnRH receptor has been identified in mammalian species, there 
is a body of evidence indicating the existence of at least two forms of GnRH in most 
vertebrates (King and Millar, 1987, 1990, 1992) and the existence of GnRH receptor subtypes 
(Murthy and Peter, 1994; Murthy et al., 1994). In particular, chicken GnRH II 
([His5,Trp7,Tyr8]-GnRH) is present in most vertebrates. It has been structurally conserved 
over 500 million years of evolution and appears to serve a neuromodulatory role. This peptide 
has more recently been identified in certain mammalian species (King et al., 1989; King et 
al., 1990; Dellovade et al., 1993; King et al., 1994). Since the receptor for chicken GnRH II 
has not been revealed by molecular cloning, it may have poor structural homology with the 
cloned mammalian receptors or even be structurally unrelated, as is the case for the nicotinic 
and muscarinic receptors which both bind acetyl choline, but belong to different receptor 
families. This novel receptor could potentially be identified by purification and partial amino 
acid sequencing followed by molecular cloning. In addition to GnRH receptors, other proteins 
may be regulated by binding of GnRH or GnRH breakdown products. Indeed, it has recently 
been demonstrated that the activity of a hypothalamic N-Methyl-D-Aspartate receptor is 
regulated by a GnRH fragment (Bourguinon et al., 1994). 
This study describes the development of a GnRH agonist affinity chromatography 
protocol for purification of proteins which bind GnRH, and the purification of a 67 kD protein 
from sheep pituitary membranes. The purified protein is different from the cloned GnRH 
receptors and may have a function in processes modulated by GnRH or by GnRH breakdown 
products, similar to the recently described regulation of hypothalamic N-Methyl-D-aspartate 
receptors by a GnRH fragment (Bourguignon et al., 1994). 
MATERIALS AND METHODS 
Peptides 
The GnRH agonist, [D-Afa6,N-MeLeu7,Pro9-NHEt]-GnRH, and the D-Lys6-containing 
GnRH analogues, [His5,D-Lys6,Trp7,Tyr8]-GnRH, [D-Lys6,Trp7,Tyr8]-GnRH, [D-
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Lys6,Trp7,Gin8]-GnRH and [D-Lys6,Trp7,Leu8]-GnRH were prepared by R. Milton, using 
conventional solid phase peptide synthesis. [D-Lys6,Pro9-NHEt]-GnRH was a gift from J. 
Rivier and antagonist 26, [Ac-D-4-Cl-Phel.2,D-Trp3,D-Lys6,D-Alal<>J-GnRH, was a gift from 
D.Coy. 
Plasma membrane preparation and solubilization 
Sheep pituitary membrane preparation was modified somewhat from that described in 
chapter 2. Sheep pituitaries were collected on to ice within 30 min of death at the Cape Town 
Municipal Abattoir. Anterior pituitaries were dissected free of bone and membranes within 2 
hs and frozen at -70° C for up to 30 days or used immediately for membrane preparation. 
Batches of up to 40 fresh or frozen pituitaries were minced with a scalpel blade and 
homogenized in ice cold HEPES buffer (lOmM HEPES, lmM EDTA, pH 7.4, 3ml/pituitary) 
using a Polytron (3 short bursts at moderate speed). We found higher binding in HEPES 
buffer compared with the tris-HCl buffer used in chapter 2. In addition, dithiothreitol was 
omitted because it has been reported to decrease receptor binding affinity (Keinan and 
Hazum, 1985). The homogenate was centrifuged for 10 min at 500 x g and 4° C to remove 
debris. The resulting supernatant was layered on top of 50% sucrose (10 ml) and centrifuged 
for 30 to 40 min at 180,000 x g and 9° C (45,000 rpm in a Beckman 50.2 Ti rotor). This step 
was necessary to remove the component which caused high non-specific binding in the ligand 
binding assay (chapter 2). The relatively high temperature was important because at lower 
temperatures (4° C) the particulate material did not separate into discreet interface and pellet 
components, but was distributed throughout the sucrose. The opaque fraction at the interface 
between the buffer and sucrose was collected, diluted (approximately 4-fold) with HEPES 
buffer and recentrifuged for 30 to 40 min at 180,000 x g and 4° C. The resulting pellets were 
resuspendetl in the same buffer (3 pituitary equivalents/ml) using a 0.8mm diameter needle 
and syringe, and stored at -70° C or immediately solubilized. 
Pituitary membranes were diluted to a final concentration of 1 pituitary equivalent/ml 
with HEPES buffer containing 4mM CHAPS (3-[(cholamidopropyl)dimethyl-ammonio] 1-
propanesulfonate, Sigma. St Louis, USA) and solubilized by shaking on ice for 1 h. In 
preliminary experiments CHAPS (1 - 100 mM), octyl glucopyranoside (Sigma. 12.5 -200 
mM), Tween 20 (0.03 -1 %) and Triton X-100 (0.06 - 0.48 mM) were tested. The resulting 
mixture was diluted with an equal volume of HEPES buffer and centrifuged for 1 h at 
180,000 x g and 4° C to remove particulate material. The supernatant was used immediately 
for affinity chromatography or for binding experiments. 
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Affinity chromatography 
For pilot experiments, GnRH analogues containing D-Lys in position 6 were coupled to 
Affi-Gel 10 beads (Biorad, Richmond, USA). Resin suspension (1 ml) was washed with 
ethanol then with HCl diluted to pH 2.5 - 3.0 and incubated at 4° C with peptides (5 - 30 
nmol) in 1 ml lOmM HEPES (pH 7.4) for 2 - 4 h with shaking. Unreacted sites on the resin 
were blocked by incubation with lM ethanolamine (1 h, room temperature) and the affinity 
resin was washed with, and stored in HEPES buffer. To test their capacity to bind GnRH 
receptor, affinity resins were mixed with solubilized pituitary membranes, diluted to lmM 
CHAPS, and incubated for 1 hon ice with shaking. Suspensions were centrifuged (4° C, 10 
min, 10,000 x g) and the supernatant tested for GnRH agonist binding. 
For preparative affinity chromatography, the more rigid Affi-Prep 10 resin (Biorad, 
Richmond, USA) was used to allow the solubilized membrane preparation to be pumped on to 
the column at higher speed without compression of the resin. [D-Lys6,Pro9-NHEt]-GnRH (1.5 
- 2.9 µmol in 2 - 10 ml of 50mM or lOmM HEPES, pH 7.4) was coupled to Affi-Prep 10 (4 -
8 ml) as described above for Affi-Gel 10 and stored in HEPES buffer. 
Solubilized pituitary membranes (up to 40 pituitary equivalents) were diluted to a final 
CHAPS concentration of 1 mM and applied to the affinity column. Unbound material was 
washed off with approximately 3 ml of HEPES buffer containing 0.1 mM CHAPS and then 
with a 40 ml gradient of NaCl (0 - 0.4M) in O.lmM CHAPS-HEPES buffer. Bound proteins 
were eluted with an acidic HEPES buffer (O.lmM CHAPS, lmM EDTA, lOmM HEPES, pH 
5.8). 4 ml fractions were collected and neutralized with NaOH, using 10 µl phenol red (0.4 % ) 
as an indicator and tested for binding of GnRH agonist Fractions which bound GnRH agonist 
were pooled and lyophilized. 
GnR.H agonist binding assay 
Conventional GnRH receptor ligand binding assays depend on using filters to retain 
labelled ligand bound to particulate membrane receptors, while the soluble unbound ligand 
passes into the filtrate (Millar et al., 1995). This protocol had to be modified to measure 
binding of the GnRH agonist, [D-Ala6,N-MeLeu7,Pro9-NHEt]-GnRH, to solubili:zed pituitary 
membrane preparations and affmity column eluates. 400 µl of solution was incubated on ice 
for 60 - 90 min with 100,000 cpm of 125I-[D-Afa6,N-MeLeu7,Pro9-NHEt]-GnRH (specific 
activity 500 µCi/µg) in a final volume of 1 ml of HEPES buffer. The reaction was terminated 
by addition of 1 ml of ice cold dextran-coated charcoal (0.1 % w/v Dextran TIO, 1 % w/v 
activated charcoal in phosphate-buffered saline). The unbound 125I-[D-Afa6,N-MeLeu 7,Pro9-
NHEt]-GnRH is adsorbed by the dextran-charcoal, while the ligand which is bound to 
proteins remains in solution. Tubes were mixed and centrifuged for 15 min at 4° C and 2,000 
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x g. Supernatants were counted in a gamma counter (Packard Crystal II). Non-specific 
binding was estimated in the presence of 5 x 10-7M unlabelled [D-Afa6,N-MeLeu7,Pro9-
NHEt]-GnRH. This lower than the usual (10-6 M) concentration of unlabelled ligand was 
used because higher concentrations displaced labelled ligand from the charcoal causing 
artifactually raised estimates of non-specific binding. Assays were performed in duplicate or 
triplicate. Results are presented as mean specific binding ± standard error. 
[D-Afa6,N-MeLeu7,Pro9-NHEt]-GnRH was iodinated by a modification of the 
chloramine-T method and the iodinated peptide was purified by C18 reversed phase HPLC 
(Millar et al., 1995). 
Dissociation of GnRH binding proteins 
To test the ability of NaCl to promote dissociation of binding proteins prebound to 
labelled agonist, total and non-specific binding tubes were set up as above and preincubated 
for 1 h to allow binding to occur. After addition of 200 µl aliquots of NaCl to give the 
required concentrations, tubes were incubated for various times and treated with charcoal as 
above. A similar protocol was used to test the effect of changes of pH. Membranes were 
preincubated in tris-acetate (lOmM, pH 7.5) before addition of previously determined 
volumes of tris-acetate buffers at pH 3.5 and pH 10.0 and incubated in a final volume of 2 ml 
before addition of dextran-coated charcoal. To test whether treatment with extremes ·of pH 
would affect the ability of the solubilized pituitary membrane preparation to subsequently 
bind GnRH agonist. membranes were solubilized in tris-acetate buffer (pH 7 .5) and were not 
diluted prior to the centrifugation step. 1ml aliquots were adjusted to the pH indicated using 
tris or acetic acid and incubated for 4 h in a total volume of 4 ml. Samples were then 
neutralized using phenol red as an indicator and diluted to 5 ml. 1.2ml aliquots were used to 
measure agonist binding activity in a 1.5 ml final assay volume. 
SDS polyacrylamide gel electrophoresis and western blotting 
SOS polyacrylamide gels were run under reducing conditions according to the method 
of Laemmli (1970). Analytical gels were prepared with 7% acrylamide or a gradient of 7 -
11 % and proteins were detected by silver staining (modified from Oakley et al., 1980, J. 
Hapgood, personal communication). Briefly, gels were Coomassie-stained overnight and 
destained in 30% methanoV10% acetic acid, then incubated sequentially in 50% 
methanoV12% trichloroacetic acid/2% CuC12 (30 min); 10% ethanoV5% acetic acid; 0.01 % 
KMn04; 10% ethanoV5% acetic acid; 10% ethanol; water; 0.1 % AgN03 (15 min each) and 
washed briefly with water and 10% K2C03. Colour was developed using 0.01% 
fonnaldehyde in 2% K2C03. Gels used to estimate the protein concentration of the final 
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product and for western blotting contained 1 M tris in both the stacking and running gels. The 
higher buff er concentration helped to minimize the anomalies which arise from high 
electrolyte concentrations in samples. Proteins for molecular weight calibration and sheep 
serum were dissolved or diluted in "reconstitution buffer" (3.0M HEPES, pH 7.5, 0.3M 
CHAPS, 0.01 % phenol red) to mimic the reconstituted lyophilized sample before being mixed 
with an equal volume of application buffer. 
Since the affinity purified binding protein exhibited mobility similar to that of BSA in 
SOS-PAGE, western blotting experiments were perfonned to confirm that the purified protein 
was not sheep serum albumin. An aliquot of the purified protein and various dilutions of 
sheep serum were electrophoresed as described above and electroblotted (1 h, 4° C, 0.5 mA) 
on to a Nytran N nylon membrane (Schleicher and Schoell, Dassel, Germany). The 
membrane was blocked for 3 hs in tris-buffered saline (TBS, 0.1 M NaCl, 50 mM tris, pH 8.0) 
containing 20% (w/v) fat free milk powder (Borden Foods, Braamfontein, South Africa), 
washed 3 times in TBS containing 5% milk powder and incubated overnight in 15 ml of the 
same buffer containing 250 µl of rabbit anti-sheep whole serum (Sigma, St Louis, USA). The 
membrane was washed 4 times and incubated for 30 min with horse radish peroxidase-
conjugated goat anti-rabbit lg G (100 µl in 15 ml, Bio-Rad, Richmond, USA). After washing 
with 5% milk TBS and with TBS, proteins were visualized with 4-chloro-1-naphthol (60 mg 
in 20% methanol/IBS containing 100 µl 30% H20i). Albumin was the major protein in the 
sheep serum and, at the concentrations of sheep serum used, it was the only protein detected 
by the antiserum. 
RESULTS AND DISCUSSION 
Several detergents, CHAPS, octyl glucopyranoside, Tween 20 and Triton X 100, were 
tested at various concentrations for their ability to solubilize GnRH agonist binding activity. 
Only CHAPS allowed recovery of binding activity in the soluble fraction. Maximum 
solubilization of specific GnRH agonist binding was found after treatment with 4mM CHAPS 
(fig. 3.1), similar to the concentration shown to be optimal for solubilization of bovine and rat 
pituitary GnRH receptors (Winiger et al., 1983; Perrin et al., 1983; Hazum et al., 1986), and 
this concentration was used for further studies. The CHAPS concentration was not adjusted to 
a defined concentration across all tubes in the binding assay, as this experiment was also 
intended to indicate the effect of the residual CHAPS on subsequent binding of the 
solubilized preparation to the GnRH analogues attached to the affinity columns. 
Both the amino- and carboxy-termini of the GnRH molecule are blocked, and the 
peptide contains no residues with free carboxyl, amino or sulfbydryl groups. Thus, a reactive 
group must be introduced into the peptide to allow it to be coupled to affinity resins. GnRH is 
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Figure 3.1 Solubilization of GnRH agonist binding activity. Sheep pituitary membranes 
were incubated, with shaking, in the indicated concentrations of CHAPS, diluted and 
centrifuged to remove particulate material. Binding assays were performed on the resulting 
supernatant. 
believed to interact with its receptor in a folded conformation such that both termini are 
necessary for high affinity binding (Karten and Rivier, 1986). For this reason, modification of 
residues in the terminal regions of the molecule is undesirable. However, substitution of the 
achiral glycine residue in position 6 with D-amino acids stabilizes the preferred peptide 
conformation, increasing GnRH activity (Monahan et al., 1973; Momany, 1976a) and 
increasing the affinity of GnRH binding to its receptor (Millar et ai., 1989; chapter 2). Six 
GnRH analogues, in which D-Lys, which contains a free amino group, was substituted for 
Gly6, were tested for their ability to bind to the GnRH receptor. Two analogues, [D-
Lys6,Pro9-NHEt]-GnRH and antagonist 26, exhibited high affinity for the receptor while the 
other peptides exhibited lower affinities (fig. 3.2a), characteristic of analogues with 
substitutions in position 8 (Millar et al., 1989; chapter 2 of this thesis). Harsh conditions are 
frequently required to disrupt high affinity interactions in order to elute proteins of interest 
These harsh conditions can denature the proteins. Thus7 using an affinity column prepared. 
with a lower affinity ligand might help reduce damage to the GnRH binding proteins. To test 
this propo5a4 affinity supports were prepared with each of the peptides. All supports bound 
GnRH receptor (fig. 3.2b). However7 only the resins prepared. with the two high affinity 
analogues bound more than 50% of the GnRH receptor applied (fig. 3.2b). Affinity columns 
were prepared with both of these resins. 
If peptide ligands arc used to elute the GnRH receptor from the affinity column7 eluted 
fractions contain large amounts of peptide which interfere in the. competitive binding assay 
used to quantify the receptor. Non-peptide eluting agents, which would allow subsequent 
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measurement of the receptor by ligand binding assays, were thus sought. Previous reports had 
shown that salts inhibit GnRH agonist binding (Hazum, 1987). We therefore tested whether 
incubation with NaCl would promote dissociation of the GnRH receptor prebound to a 
labelled GnRH analogue. Preformed complexes of GnRH receptor and 125I-[D-Ala6,N-
MeLeu7,Pro9-NHEt]-GnRH were stable for at least 30 min in the presence of up to O.SM 
NaCl (fig. 3.3a). In contrast, increasing the hydrogen ion concentration did promote 
dissociation of prebound receptor-agonist complexes. Incubation for 30 min at pH 6 or lower 
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Figure 3.2 Competition binding assay of GnRH analogues containing D-Lys in position 6 
and residual GnRH binding activity in solubilized pituitary membranes after incubation 
with affinity supports prepared with the same peptides. Competition binding assays (a) 
were perf onned as described in the text. Solubil.i7.ed pituitary membranes were incubated with 
the indicated affinity supports (b ). GnRH binding activity is expressed as the per cent of 
GnRH binding activity in a preparation incubated with affinity support to which no peptide 
was coupled. Peptides are: antagonist 26 (0, l); [D-Lys6,Pro9-NHEt]-GnRH ( •, 2); [His5,D-
Lys6,Trp7,Tyr8]-GnRH (V, 3); [D-Lys6,Trp7,Tyr8]-GnRH (T, 4); [D-Lys6,Trp7,a1n8]-GnRH 
(o, 5) and [D-Lys6,Trp7,Leu8]-GnRH (•, 6). 
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Figure 3.3 Effect of NaCl and pH on preformed GnRH receptor-agonist complexes and 
recovery of GnRH binding activity after incubation at low pH. Solubilized pituitary 
membranes were incubated with 125I-[D-Afa6,N-MeLeu7,Pro9-NHEt]-GnRH, before addition 
of NaCl (a) to give the indicated concentrations and incubation for a further 5 min 
( • ), 10 min ( •) or 30 min ( • ). After incubation to allow 125I-[D-Afa6,N-MeLeu 7,Pro9-
NHEt]-GnRH to bind, pH was adjusted (b) as indicated and incubation continued for a further 
20 min ( • ), 30 min ( "-) or 1 h ( • ). Solubilized pituitary membranes were incubated at the 
pHs indicated (c) prior to neutralization and measurement of GnRH binding activity. · 
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caused complete dissociation of labelled GnRH agonist (fig. 3.3b). To test whether high 
affinity binding could be recovered after treatment with acid, solubilized pituitary membranes 
were incubated at low pH and neutralized before GnRH agonist binding activity was 
measured. Binding activity was recovered in samples pre-incubated at pH values greater than 
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Figure 3.4 GnRH binding activity and SDS-PAGE analysis of affinity chromatography 
fractions. GnRH agonist binding assays (a) were performed on aliquots of the starting 
material (1), the same material after passage through the column (2), the pooled material 
collected during the NaCl gradient (3) and the acid-eluted fraction (4). SOS-PAGE utilized 
aliquots of the starting material (lane 1 ), the same material after passage through the column 
(lane 2), and the NaCl gradient (lane 3) and the entire acid-eluted fraction (lane 4). 
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4.5 (fig. 3.3c). The conclusions from these experiments were that since NaCl did not disrupt 
receptor ligand complexes, it might provide a useful column washing step to remove non-
specifically bound proteins, while the GnRH binding activity could be eluted from the column • 
with a low pH (between pH 4.5 and 6.0) buffer. Binding activity could then be measll!'ed in 
the acid-eluted fractions after neutralization. 
Greater than 90% of the GnRH binding activity in solubilized pituitary membrane 
preparations applied to the affinity columns was retained by the columns (fig. 3.4a). GnRH 
agonist binding was not detected in fractions collected during the gradient of NaCl (fig. 3.4a). 
However, as anticipated, GnRH binding activity was eluted from the [D-Lys6,Pro9-NHEt]-
GnRH column by the acidic binding buffer (fig. 3.4a). This protocol did not elute binding 
activity from the affinity column prepared with antagonist 26 (not shown). Antagonist 26 has 
been shown to form a "functionally irreversible complex" with the GnRH receptor (Loumaye 
et al., 1984) and it is possible that low pH does not promote dissociation of this antagonist 
from the receptor in the same way as it does agonists. SDS-PAGE analysis of fractions 
a 1 2 3 4 5 6 b 6 5 4 3 2 1 
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Figure 3.5 SDS-P AGE and western blot showing that the purified protein is not sheep 
serum albumin. Sheep serum at various dilutions and an aliquot of the pooled fractions 
eluted from the affinity columns were electrophoresed as described under experimental (a) 
and western blotted (b). Lanes marked 1 - 5 contain sheep serum diluted 1:4 000; 1:8 000; 
1:16 000; 1:32 000 and 1: 64 000 while lane 6 contains the acid-eluted protein. 
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collected from the [D-Lys6,Pro9-NHEt]-GnRH affinity column showed that the NaO gradient 
up to 0.4 M did indeed elute a large number of proteins which were probably only loosely 
bound to the column by non-specific interactions (fig. 3.4b). This therefore constituted an 
important, albeit unusual clean-up step in the purification. 
The acid-eluted fractions, which were pooled and lyophilized to concentrate them, 
exhibited a major protein band and a minor band (fig. 3.4b ). However, their apparent relative 
molecular weights of 59 kD and 56 kD are probably inaccurate because the high electrolyte 
concentration of the lyophilized sample caused this lane to run differently from ·the other 
lanes on the gel (fig. 3.4b). The lane was about 4 times wider than the other lanes and the dye 
front moved more slowly. For subsequent gels, molecular weight markers were dissolved in a 
buffer similar to the reconstituted lyophilized sample. We also found that increasing the 
buffer concentration in the gels, as described under "experimental", resulted in an even dye 
front and helped prevent lane broadening. However, resolution of the bands was 
compromised (fig. 3.5 for example). The [D-Lys6,Pro9-NHEt]-GnRH column was used for all 
subsequent purifications. Binding activity recovered in the acid-eluted fractions of subsequent 
affinity chromatography runs ranged from 3.5 - 16.2 % of that in the solubilized material 
applied to the columns. 
Lyophilized acid-eluted fractions from seven affinity column runs (278 pituitaries) were 
pooled. The high concentrations of residual buff er components in the reconstituted mixture 
caused interference in conventional protein assay methods. Thus, protein concentration was 
estimated by comparison of an aliquot of the mixture with a BSA standard curve using 
modified SOS polyacrylamide gel electrophoresis. The mixture contained approximately 10 
µg (equivalent to 150 pmol) of a protein which migrated as a single band with Mr 67 kD. This 
molecular weight is slightly higher than the 57 to 64 kD determined by photoaffinity labelling 
or western blotting of GnRH receptors in pituitaries of other mammalian species (Iwashita 
and Catt, 1985; Eidne et al., 1985; Hazum et al., 1986; Perrin et al., 1993). It is also higher 
than the molecular weight predicted from the deduced amino acid sequence of the recently 
cloned sheep GnRH receptor (Illing et al., 1993; Brooks et al., 1993). Although the actual 
molecular weight of the cloned receptor is likely, due to post-translational glycosylation, to be 
higher than the predicted minimum, the cloned sheep GnRH receptor has fewer glycosylation 
consensus sequences than the rat and mouse receptors. It is, thus, unlikely to migrate with a 
higher apparent molecular weight than the rat and mouse GnRH receptors. In addition, the 
protein purified here does not exhibit the band broadening, characteristic of photoaffinity-
labelled GnRH receptors, caused by heterogeneous glycosylation (Janovick et al., 1993; 
Davidson et al., 1995). However, it is similar to the 66kD protein which co-purified with the 
rat GnRH receptor (Hazum et al., 1986) and which was thought, by the authors, to be residual 
BSA used to coat affinity columns. BSA was not used in the current study, but small 
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quantities of sheep serum albumin present in the pituitary tissue could have adhered to the 
column and eluted with the GnRH receptor. Western blotting showed that the protein is not 
ovine serum albumin (fig. 3.5). 
Lyophilized fractions containing the affinity purified 67kD protein were resuspended in 
purified (Milli-Q) water (5ml) and dialyzed extensively against 0.02% SOS (in water) to 
remove detergent, buffer components and phenol red. The dialyzed sample was concentrated 
by vacuum centrifugation (Speed-Vac, Savant) and the 67kD protein resolved by SOS-Page 
under reducing conditions. The gel-purified protein (with an estimated recovery of less than 
50 pmol) was subjected to in situ tryptic cleavage and peptides were recovered by HPLC 
extraction (Tetaz et al., 1993). Microsequence analysis of several peaks revealed mainly 
sequences which were homologous to human epidermal type II keratins (Johnson et al., 1985; 
Tyner et al., 1985). However, subtraction of a keratin-derived sequence from one double 
sequence revealed the sequence LXYQL (X=unknown), which showed homology to the 
tryptic peptide sequence (L VYQL) derived from a GnRH-binding protein recently purified 
from bovine pituitary (Christiansen and Houen, 1994). 
The GnRH binding protein purified from bovine pituitaries (Christiansen and Houen, 
1994) exhibited properties similar to those of the protein described here. Its apparent Mr was . 
estimated to be 60 kD by SOS-PAGE analysis of samples lyophilized in phosphate-buffered 
saline. The protein did not exhibit the band broadening characteristic of glycosylated GnRH 
receptors. In addition, partial amino acid sequencing showed that it was not the bovine GnRH 
receptor. However, it is probably the bovine homolog of the protein which we have purified 
from sheep pituitary as both proteins contain the tryptic peptide sequence LXYQL. This 
purification of the same protein from different, although closely related, species using 
different affinity chromatography protocols, suggests that the protein purified here may bind 
GnRH or part of the GnRH molecule. It may have a physiological role which is regulated by 
GnRH or, as has recently been described for an N-Methyl-0-aspartate receptor, by a fragment 
of GnRH (Bourguignon et al., 1994) 
In conclusion, we have purified a 67kD protein which bound to a GnRH agonist affinity 
column. It was not eluted from the affinity column by high salt concentrations, but was 
dissociated from the immobilized GnRH agonist by an acidic buffer. The eluted preparation 
retained GnRH binding activity. The protein does not exhibit the broad band on SOS-PAGE 
which is characteristic of the heterogeneously glycosylated GnRH receptor and amino acid 
sequence analysis showed that it is not the gene product of the recently cloned sheep GnRH 
receptor (Brooks et al., 1993; Illing et al., 1993). The sequence is, however, homologous with 
that of a bovine pituitary protein recently purified by a different GnRH affinity 
chromatography protocol and partially sequenced (Christiansen and Houen, 1994). Since both 
of these proteins bound to immobilized GnRH agonists, they may have a biological function 
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which is modulated by binding of GnRH or a GnRH fragment. 
While we were in the process of developing a technique for separating the protein 
described in this study from the residual buffer components without losing it, the mouse 
GnRH receptor was cloned by our collaborators. I participated in studies to characterize the 
ligand binding properties of the first cloned GnRH receptor (Tsutsumi et al., 1992) as well as 
those of the human (Chi et al., 1993) and sheep GnRH receptors (Illing et al., 1993), which 
were subsequently cloned form cDNA libraries (Also see chapter 6, Other studies conducted 
during the course of this thesis). The cloned mouse GnRH receptor was mutated m order to 
study the GnRH receptor ligand binding domain as described in chapter 4. 
CHAPTER4 
GLUTAMATE30I OF THE MOUSE GnRH RECEPTOR CONFERS SPECIFICITY 
FOR ARGININES OF MAMMALIAN GnRH 
SUMMARY 
The Arg residue in position 8 of mammalian GnRH is necessary for high affinity 
binding to mammalian GnRH receptors. This requirement has been postulated to derive from 
an electrostatic interaction of Arg8 with a negatively-charged receptor residue. In order to 
identify such a residue, eight conserved acidic residues of the mouse GnRH receptor, Glu8, 
Asp90, Asp98, Glulll, Asp185, Asp292, Glu294 and Glu301, were mutated to isosteric Asn or 
Gln. Mutant receptors were tested for decreased preference for Arg8-containing ligands by 
ligand binding and inositol phosphate production. 
One of the mutants, in which the Glu301 residue was mutated to Gln, exhibited a 56-fold 
decrease in apparent affinity for mammalian GnRH. The mutant receptor also exhibited 
decreased affinity for [Lys8]-GnRH, but its affinity for [Gin8]-GnRH was unchanged 
compared with the wildtype receptor. The apparent affinity of the mutant receptor for the 
acidic analogue, [Glu8]-GnRH, was increased more than IO-fold. The mutant receptor did not, 
therefore, distinguish mammalian GnRH from analogues with amino acid substitutions in 
position 8 as effectively as did the wildtype receptor. This loss of discrimination was specific 
for the residue in position 8, because the mutant receptor did distinguish mammalian GnRH 
from analogues with favourable substitutions in positions 5, 6 and 7. These findings show that 
the Glu301 residue of the GnRH receptor plays a role in receptor recognition of Arg8 in the 
ligand and are consistent with an electrostatic interaction between these two residues. 
The mutant receptor exhibited high affinity for conformationally constrained analogues 
of GnRH, showing that the Glu301 and Arg8 residues are not required for the high affinity 
interactions of conformationally constrained peptides. This indicates that an interaction 
involving these two residues may induce changes in the conformation of GnRH after it has 
bound to the receptor. 
INTRODUCTION 
In mammalian GnRH there is a positively charged Arg residue in position 8, which is 
necessary for high affinity and specificity of binding to mammalian GnRH receptors 
(GnRHR). In contrast, GnRHs from most non-mammalian vertebrates contain uncharged 
residues in position 8 (King and Millar, 1992). Although these non-mammalian GnRHs are 
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fully active in the animals in which they occur naturally, they show diminished capacity to 
stimulate release of gonadotropins from mammalian pituitary cells (King and Millar, 1992; 
chapter 2) and to stimulate inositol phosphate (IP) production in cells transfected with 
mammalian GnRHRs (Illing et al., 1993). Experiments using synthetic GnRH analogues have 
confirmed the importance of a positively-charged amino acid in position 8 for high-affinity 
interaction with mammalian GnRHRs (Sandow et al., 1978; Karten and Rivier, 1986; Millar 
et al., 1989; chapter 2). 
It has been postulated that the Arg8 sidechain may interact directly with the dnRHR via 
an electrostatic interaction with a negatively charged Asp or Glu residue (Hazum, 1987) or 
with a sialic acid residue in the carbohydrate moiety of this glycoprotein (Keinan and Hazum, 
1985). A functional GnRHR was first cloned from the mouse aT3 gonadotrope cell line 
(Tsutsumi et al., 1992). This, and the subsequent cloning of three other mammalian GnRHRs 
(Eidne et al., 1992; Kaiser et al., 1992; Kakar et al., 1992; Brooks et al., 1993; Illing et al., 
1993; Chi et al., 1993; Kakar et al., 1993; Perrin et al., 1993; Weesner and Matteri, 1994), 
have allowed the application of site-directed mutagenesis in identifying amino acid residues 
which determine the specificity of mammalian GnRHRs for GnRHs which contain Arg in 
position 8. 
The ligand binding sites of heptahelical, G-protein-coupled neurotransmitter receptors 
are contained within the transmembrane helical bundle (Strader et al., 1989; Dohlman et al., 
1991; Strader et al., 1994). However, the larger size of peptide hormones suggested that the 
extracellular loops of their receptors may also participate in ligand binding functions. To test 
the possibility that the high affinity of mammalian GnRH, which contains Arg8, is dependent 
on an acidic residue, we systematically mutated conserved acidic residues in the extracellular 
and transmembrane domains of the mouse GnRHR. We show here that one of these mutant 
receptors, the [Gin301]-GnRHR, displayed decreased ligand binding affinity for mammalian 
GnRH, but affinities for GnRH analogues with uncharged residues in position 8 were 
unchanged or increased. 
MATERIALS AND METHODS 
Peptides 
GnRH, [Gln8]-GnRH (chicken GnRH n, chicken GnRH II ([His5,Trp7,Tyr8]-GnRH), 
[D-Afa6,N-MeLeu7,Pfo9-NHEt]-GnRH, [D-Trp6]-GnRH. [D-Trp6,Pro9-NHEt]-GnRH and 
[D-Trp6,a1n8,Pro9-NHEt]-GnRH were prepared by conventional solid-phase methodology 
and purified by preparative C18 reversed-phase chromatography. [Glu8]-GnRH and [His8]-
GnRH were gifts from R.W. Roeske and [Lys8]-GnRH was a gift from J. Rivier. 
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Mutagenesis and transfection 
The mouse GnRHR was cloned into pBluescript II SK + (Stratagene, La Jolla, CA) and 
site-directed mutagenesis was perfonned using Uracil-containing DNA (Kunkel et al., 1991) 
for [Gln8]-GnRHR, [Ginlll]-GnRHR, [Asn185]-GnRHR, [Asn292]-GnRHR, [Gin294]-
GnRHR and [Gin301]-GnRHR. For [Gln90]-GnRHR and [Asn98]-GnRHR, the mouse GnRHR 
was cloned into the pAL TER TM.1 vector and mutated using Altered Sites in vitro 
mutagenesis system (Promega). To confirm mutagenesis, DNA was sequenced manually, 
using a Sequenase Kit (USB, Cleveland, OH) or by automated sequencer (Biorad, Richmond, 
CA). The receptor was subcloned into the expression vector pcDNAI/ Amp (Invitrogen Corp., 
San Diego, CA) and mutation sites were resequenced. 
COS-1 cells were transiently transfected with pcDNAJ/Amp-GnRHR constructs using a 
modification of the DEAE-dextran method (Keown et al., 1990) as previously described (Chi 
et al., 1993). 2.5µg of DNA construct was used per well in 12-well plates for IP assays and 
15µg DNA per 9 cm dish for ligand binding assays. Receptor expression ranged from 150 to 
600 fmol per 106 cells for the wildtype GnRHR and from 35 to 150 fmol per 106 cells for the 
[Gln301]-GnRHR. 
Inositol phosphate (IP) production 
Transfected cells were labelled overnight with [3H]-inositol (2 µCi/ml) and stimulated 
with GnRH or GnRH analogues for 1 h in the presence of LiCl (lOmM). The reaction was 
terminated by addition of a perchloric acid solution and phytic acid. After neutralizing with 
KOH, IPs were separated on Dowex ion exchange columns and counted (Davidson et al., 
1990). 
Radioligand binding assay 
Ligand binding assays with the wildtype GnRHR and the screening ligand binding 
assay were performed as previously described (Chi et al., 1993). Briefly, transfected COS-1 
cells were detached from culture dishes in binding buffer (lOmM HEPES, pH 7 .4, lmM 
EDTA, 0.1 % BSA, fatty acid free), homogenized with a dounce homogenizer and centrifuged 
at 15 000 x g for 30 min at 4° C. The crude membrane pellet was resuspended in binding 
buffer and incubated (7.5 x 105 cell equivalents/tube, -200 fmol receptor) with 60 000 cpm 
125I-[D-Aia6,N-MeLeu7,Pro9-NHEt]-GnRH (-50pM) and varying concentrations of 
unlabelled test peptides in a final volume of 0.5 ml for 1 to 1.5 h on ice. The incubation was 
terminated by the addition of 3 ml phosphate-buffered saline (PBS, pH 7.5) containing 0.1 % 
BSA and immediate filtration through glass-fibre filters (GF/C, Whatman) presoak:ed in PBS 
containing 1 % BSA. The filters were washed twice with 0.1 % BSA PBS and the retained 
radioactivity was counted. Non-specific binding was estimated in the presence of 10-7M 
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unlabelled [D-Afa6 ,N-MeLeu 7,Pro9-NHEt]-GnRH. 
To compensate for the lower total binding of 125I-[D-Afa6,N-MeLeu 7,Pro9-NHEt]-
GnRH exhibited by the [Gin301]-GnRHR, higher concentrations of membranes (1.2 x 106 cell 
equivalents/tube, -75 fmol receptor) were used for subsequent experiments on . the mutant 
receptor. Also, to avoid dissociation of the labelled ligand from the lower affinity receptor, 
the dilution step at the end of the assay was eliminated and the filters washed 4 times under 
vacuum with 0.1 % BSA PBS to remove non-specifically bound l25I-[D-Afa6,N-
MeLeu 7,Pro9-NHEt]-GnRH. Increasing amounts of the pcDNAI/Amp-[Gin301]-GnRHR 
construct in the transf ection reaction showed that maximal expression of the mutant receptor 
was achieved with 15µg DNN9cm dish of cells, the same as with the wildtype GnRHR 
construct Binding of 125I-[D-Afa6,N-MeLeu 7,Pro9-NHEt]-GnRH was maximal after 
incubation for 75 min and remained stable for a further 75 min. Specific binding ranged from 
2004 to 4518 cpm/tube (0.8 to 1.9 fmol, compared with 11700 to 20543 cpm/tube, 4.8 to 8.6 
fmol, with wildtype GnRHR) while non-specific binding ranged from 2189 to 3228 cpm/tube 
(0.9 to 1.3 fmol). 
Data analysis 
Peptide concentrations required to half-maximally inhibit binding of l25I-[D-Ala6,N-
MeLeu7,Pro9-NHEt]-GnRH (IC50s) and to stimulate half-maximal IP production (EC5os) 
were estimated by four-parameter non-linear curve fitting using Sigmaplot (Jandel Scientific, 
Corte Madera, CA). Binding assays were performed in triplicate and IC5os were determined 
in three to five independent experiments. IC50 data in table 4.1 are means ± standard error of 
all experiments. Competitive binding curves for some GnRH peptides exhibited slopes which 
render Hill coefficients not equal to one. For this reason, we have reported IC5os as indicators 
of apparent ligand binding affinity and supported our observations of changes in apparent 
affinity by measuring ECsos for IP production in response to all GnRH peptides. Apparent 
dissociation constants CKcts) were calculated from ICsos using the Munson and Rodbard 
correction (Munson and Rodbard, 1988) to allow estimation of of changes in binding energy 
of receptor peptide complexes using the formula AG~RTln(Kd(mutant/Kd(wildtypeV· IP assays 
were performed in duplicate and EC50S were determined in two or three independent 
experiments. EC50 data in table 4.1 are the mean ± standard error of all experiments. For 
figures 3 through_ 6,...individual IP and binding data points from all experiments were averaged 
and curves were drawn using four-parameter non-linear curve-fitting as above. 
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RESULTS 
Identification of a mutant GnRHR which did not discriminate GnRH and [G/n8J-GnRH 
We identified eight acidic amino acid residues (fig. 4.1) in the extracellular and 
superficial transmembrane domains of the mouse GnRHR which are conserved as acidic 
residues in all of the cloned GnRHRs, and which were therefore candidates for interaction 
with Arg8 of GnRH. If the Arg8 of GnRH were to interact directly with one of the acidic 
residues of its receptor, a mutant GnRHR in which this interaction is disrupted would be 
expected to have low affinity for the 125I-[D-Afa6,N-MeLeu 7,Pro9-NHEt]-GnRH used in the 
receptor binding assay. Because this decreased affinity would result in low specific binding of 
the labelled GnRH agonist, mutant GnRHRs were first screened for their ability to support 
GnRH-stimulated IP production. 10-8M GnRH is just sufficient to stimulate maximal IP 
production in the wildtype GnRHR. A mutant GnRHR with decreased affinity for GnRH, but 
normal coupling to phospholipase C should exhibit decreased IP production in response to 
Figure 4.1: The amino acid sequence and pro~ secondary structure of the mouse 
GnRHR. Conserved acidic residues in the extracellular and superficial transmembrane 
domains are indicated by their sequence numbers and bold typeface. 
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10-8M GnRH, but a nonnal maximal response to 10-SM GnRH. 
Systematic substitution of six acidic residues Glu8, Glu90, Glulll, Asp185, Asp292 and 
Glu294 with their isosteric amides did not cause large changes in the ability of the mutant 
GnRHRs to support GnRH-stimulated IP production (fig. 4.2). Two GnRHR mutants, 
[Asn98]-GnRHR and [Gin301]-GnRHR, demonstrated reduced IP production in response to 
10-8M GnRH (fig. 4.2). Of these, only the [Gin301]-GnRHR demonstrated a full response to 
10-SM GnRH (fig. 4.2). In a screening ligand binding assay, all mutant GnRHRs except 
[Asn98]-GnRHR exhibited specific binding of 125I-[D-Ala6,N-MeLeu7,Pro9-NHEt]-GnRH 
(data not shown). 
In competitive ligand binding assays the [Gin301]-GnRHR showed decreased apparent 
affinity for GnRH, but the apparent affinity for [Gin8]-GnRH was similar to that of the 
wildtype receptor (table 4.1, fig. 4.3). Both peptides showed low potency and very similar 
dose-response curves in stimulating IP production in COS-1 cells transfected with the 
[Gin301]-GnRHR (table 4.1 , fig. 4.3). 
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Figure 4.3: GnRH and [Gin8]-GnRH ligand binding and IP production in COS-1 cells 
transfected with wildtype GnRHR and [Gin301]-GnRHR. Binding of 125I-[D-Aia6,N-
MeLeu 7 ,Pro9NHEt]-GnRH (top panel) in the presence of various concentrations of GnRH ( o, 'v) and [Gin8]-GnRH (•,• ) to membranes prepared from COS-1 cells transfected with 
wildtype GnRHR (--, O , • ) or [Gin301]-GnRHR (- , '1, • ) was measured as described under 
Materials and Methods. Data points are the mean ± standard error of 3 to 5 experiments 
performed in triplicate. IP production (lower panel) in response to GnRH ( O , <v) and [Gin8]. 
GnRH ( • , •) in COS-1 cells transfected with wildtype GnRHR (--, o , •) and [Gln301]-
GnRHR (-, 'v, •) as described under Materials and Methods. Data points are the means of 2 
or 3 experiments performed in triplicate. 
Activities of other position 8-substituted GnRHs 
GnRH analogues with Lys, His or Glu substituted for Arg8 exhibited low apparent 
affinities for the wildtype GnRHR. [Lys8]-GnRH was most potent, while the negatively-
charged [Glu8]-GnRH was least potent, being unable to cause 50% inhibition of binding of 
the labelled GnRH agonist at concentrations up to 10-4 M (table 4.1, fig. 4.4). Apparent 
affinities of these peptides for the mutant [Gin301]-GnRHR were also low. The mutant 
receptor exhibited a 3-fold decreased affinity for the positively-charged [Lys8]-GnRH and 
increased affinities for [His8]-GnRH and [Glu8]-GnRH (table 4.1, fig. 4.4). 
Consistent with the ligand binding results, GnRH analogues with Lys and His residues 
in position 8 were less potent in stimulating IP production with the [Gin301]-GnRHR than 
with wildtype, while the acidic [Glu8]-GnRH showed only a small reduction in potency (table 
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4.1, fig. 4.4). [Glu8]-GnRH did not stimulate maximal IP production in cells transfected with 
either wildtype or mutant receptors (fig. 4.4). Thus, mammalian GnRH and all position 8-
substituted GnRH analogues showed low potency in activating the mutant GnRHR ( table 4.1, 
fig. 4.4). 
Other GnRH agonists 
Low affinity binding interactions are generally less specific than high affinity 
interactions. Thus, a mutation which causes general disruption of the configuration of the 
ligand binding site, rather than eliminating a specific interaction, could generate a low affinity 
receptor which also does not discriminate different GnRH analogues, as was found for the 
[Gln301]-GnRHR. To test whether this loss of discrimination was specific for modifications 
of GnRH at position 8, the activities of GnRH analogues which have high affinity due to 
modifications of other residues were tested. Chicken GnRH II ([His5,Trp7,Tyr8]-GnRH) and 
two conformationally constrained GnRH superagonists, [D-Ala6,N-MeLeu 7,Pro9-NHEt]-
GnRH and [D-Trp6]-GnRH, showed higher apparent affinity for the [Gln301]-GnRHR than 
did GnRH or analogues containing substitutions only at position 8 (table 4.1, fig. 4.5). These 
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Figure 4.5: The mutant [GJn301].GnRHR exhibits wildtype specificity for GnRH 
analogues with substitutions in positions S, 6, 7 and 10. Binding of 125J-[D-Ala6,N-
MeLeu7,Pro9Niffit]-GnRH (top panel) and IP production (lower panel) in the presence of 
various concentrations of GnRH ( O ), [Gln8]-GnRH (•),chicken GnRH II ( v ), [D-Trp6]-
GnRH ( T) and [D-Ala6,N-MeLeu7,Pro9-NHEt]-GnRH ( o) in COS-1 cells transfected with 
[Gln301 ]-GnRHR, as described under Materials and Methods. 
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peptides were also more active than GnRH and [Gln8]-GnRH in stimulating IP production in 
cells transfected with the [Gln301]-GnRHR (table 4.1, fig. 4.5). Thus, the (Gin301]-GnRHR 
exhibited high affinity for GnRH agonists containing favourable substitutions in positions 5, 
6, 7 and 10, and was able to discriminate between them and GnRH. This indicates specific 
loss of an interaction which requires Arg8, rather than a generalized decrease in binding 
affinity. 
Superagonists with- and without Arg8 
Having identified a residue (Glu301) in the GnRHR which determines the specificity of 
the receptor for Arg8 in GnRH, we addressed the question of whether this specificity 
depended on a direct interaction between the sidechains of the Arg8 and Glu301 residues or on 
the intramolecular function of Arg8 in stabilizing the preferred conformation of GnRH. To do 
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Figure 4.6: Two conformationally-comtrained analogues of GnRH exhibit high affinity 
for both the wildtype GnRHR and the [GJn301]-GnRHR mutant. Binding of 125I-[D-
Afa6,N-MeLeu7,Pro9NHEt]-GnRH (top panel) in the presence of various concentrations of 
[D-Trp6,Pro9-NHEt]-GnRH ( 0 , v ) and [D-Trp6,Gin8,Pro9-NHEt]-GnRH ( • , T ) to 
membranes prepared from COS-1 cells transfected with wildtype GnRHR (-, o , • ) or 
[Gtn301]-GnRHR (-, v, T) was measured as described under Materials and Methods. Data 
points are the mean ± standard. error of 3 to 5 experiments performed in triplicate. IP 
production (lower panel) in response to [D-Trp6,Pro9-NHEt]-GnRH ( O , v ) and [D-
Trp6,Qin8,Pro9-NHEt]-GnRH ( •, T) in COS-1 cells transfect.ecl-with wildtype GnRHR (-, 
o, •) and [Gin301]-GnRHR (-, v , T) as described under Materials and Methods. Data 
points are the means of 2 or 3 experiments performed in triplicate. 
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Table 4.2 Relative potencies of GnRH analogues containing D-amino acid substitutions 
in ~ition 6. Peptide potencies were calculated relative to GnRH using the data in table 4.1. 
wildtype GnRHR [Gln301]-GnRHR 
peptide binding IP binding IP 
GnRHAga 13.9 15.4 167 33.6 
[D-Trp~-GnRH 10.0 12.0 1000 20.9 
[D-Trp6,Pro9NHEt]-GnRH 11.2 23.8 767 92.5 
[D-T rp6, Gins ,Pro9NH Et]-GnRH 2.1 3.6 525 1009 
this we attempted to discount the intramolecular role of Arg8 by comparing the activities of 
two high affinity GnRH agonists ([D-Trp6,Pro9-NHEt]-GnRH and [D-Trp6,01n8,Pro9-NHEt]-
GnRH) in which the preferred conformation is constrained by D-Trp in position 6, and which 
differ from each other only at position 8. Both peptides exhibited high affinity binding to both 
wildtype and mutant receptors. The Gln8-containing peptide showed higher apparent affinity 
for the mutant [Gm3<H]-GnRHR than for the wildtype receptor (table 4.1, fig. 4.6). The 01ns. 
containing peptide also exhibited no loss of potency in stimulating IP production in the 
mutant receptor compared with wildtype (table 4.1, fig 4.6). The rank order of potency of the 
two peptides was reversed in the mutant [Gm301]-GnRHR, with the Gln8-containing peptide· 
more potent than the Arg8-containing peptide in stimulating IP production, although binding 
affinities were similar for both peptides (table 4.2, fig. 4.6). These results indicate that the · 
mechanism by which the Glu301 residue confers specificity for Arg8 is more complex than 
either a simple electrostatic interaction or simple stabilization of ligand conformation. 
DISCUSSION 
Eight GnRHR mutants were constructed, in which acidic residues in the superficial 
transmembrane and extracellular domains were exchanged for uncharged, hydrophilic, amide 
residues with equivalent sidechain lengths. Six mutant GnRHRs exhibited normal GnRH-
stimulated IP production in a screening assay while . two mutations caused changes in IP 
production. Mutation of Asp98 caused total loss of both agonist ligand binding and GnRH-
stimulated IP production, suggesting that this mutation may affect expression or stability of 
the receptor or disrupt the configuration of the ligand binding site. 
The [Gin301]-GnRHR mutant had characteristics consistent with loss of specificity for 
Arg in position 8 of GnRH. It exhibited low apparent affinity for GnRH, similar to the low 
apparent aff'mity of the wildtype receptor for GnRH analogues which do not contain Arg in 
position 8. Its apparent affinity for [Gln8]-GnRH was unchanged from that of the wildtype 
receptor for this ligand. However, its apparent affinity for [Glu8]-GnRH was more than 10-
72 
fold higher than that of the wildtype receptor. The mutant receptor did not clearly distinguish 
GnRH from analogues which have substitutions exclusively at position 8. Since low affinity 
interactions often lack specificity, it might be argued that the [Gln301]-GnRHR is simply a 
low affinity receptor which has lost the ability to discriminate different ligands. However, the 
[Gln301]-GnRHR retained appropriate affinities for GnRH analogues which contain activating 
substitutions in other positions. Thus, removal of the negatively-charged Glu301 residue of the 
GnRHR removed the preference of the receptor for Arg in position 8 of GnRH, but it did not 
remove the preference of the receptor for ligands with favorable substitutions in positions 5 
and 7, as illustrated by chicken GnRH II, nor did it remove the preference for a D-amino acid 
in position 6. Thus, the Glu301 residue of the mouse GnRHR determines the ability of the 
receptor to recognize Arg8 in GnRH. 
It has been proposed that the Arg8 of GnRH participates in a direct ionic interaction 
with one or more negatively charged residues in the receptor, either an amino acid sidechain 
(Hazum, 1987) or a polysaccharide sialic acid residue (Keinan and Hazum, 1985). The 
present results, combined with our recent demonstration that mutation of each of the putative 
glycosylation sites in the GnRHR does not affect ligand binding affinity (Davidson et al., 
1995), support the involvement of an amino acid sidechain, rather than a sialic acid residue, in 
the interaction of the GnRHR with Arg8. 
An electrostatic interaction is also supported by the experiments with [Glu8]-GnRH, 
which has a negatively-charged residue in position 8. The very low binding affinity (IC50 > 
10-4 M) of the wildtype GnRHR for [Glu8]-GnRH is consistent with repulsion between the 
negative charges of Glu8 in the peptide and Glu301 in the GnRHR. Removing the negative 
charge of the amino acid in position 301 of the receptor improved the apparent binding 
affinity of this negatively-charged ligand more than ten-fold (IC5o, 2.21 x 10-5 M in the 
[Gln301]-GnRHR). The apparent contribution of the Glu301 sidechain to the energy of binding 
between the GnRHR and mammalian GnRH was -2.3 kcal/mol. This is in agreement with the 
average free energies for enzyme-substrate ion-pair interactions reported for subtilisin (Wells 
et al., 1987). 
However, the mechanism by which specificity for Arg8 is conferred by Glu301 appears 
more complex than a simple electrostatic interaction. Studies with enzyme substrate 
complexes have shown that binding affinity is higher where two uncharged hydrophilic 
sidechains are in contact with each other than where an uncharged hydrophilic sidechain is in 
contact with a charged residue (Wells et al., 1987). From this it follows that, if there is contact 
between Arg8 and Glu301, the affinity of [Gln8]-GnRH for the mutant [Gin301]-GnRHR 
should be higher than the affinity of [Gln8]-GnRH for the wildtype receptor (G1n301_ __ Gin8 > 
Glu30L __ Gln8) and the mutant [Gln301]-GnRHR should exhibit higher affinity for [Gin8]-
GnRH than for mammalian GnRH (G1n30L_a1ns > Gin30l __ Arg8). This was not the case, 
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[Gln8]-GnRH had the same affinity for the mutant and wildtype receptors, and the mutant 
receptor exhibited similar affinities for GnRH and [Gln8]-GnRH. A possible explanation for 
this is that Arg8 plays an additional role in GnRH, affecting the structural conformation of the 
ligand. Like many peptides, GnRH is highly flexible in solution and exists as an equilibrium 
mixture of structural conformers. It has been proposed that the sidechain of Arg8, stabilizes a 
preferred conformation of GnRH by forming a structural unit of hydrogen bonding with the 
sidechains of His2 and Tyr5 (Shinitzky and Fridkin, 1976; Shinitzky et al., 1976; Hazum et 
al., 1977). It has also been shown that while this type of structural unit is formed in GnRH, it 
is not formed in the neutral [Gln8]-GnRH analogue (Milton et al., 1983). Other studies have 
indicated that GnRH interacts with its receptor in a folded conformation with a ~-turn which 
involves Gly6. This conformation can be stabilized by substitution of Gly6 with a D-amino 
acid, which increases GnRH activity (Monahan et al., 1973; Momany, 1976a, 1976b; 
Freidinger et al., 1980). Therefore, if Gly6 in GnRH is substituted with D-Trp, the ligand can 
be constrained in the preferred conformation, independently of whether or not there is Arg in 
position 8. This constraint makes it possible to distinguish the role of Arg8 in interacting with 
the receptor Glu301 residue from its contribution to ligand stabilization. Thus, we compared 
the apparent binding affinities, in wildtype and mutant receptors, of two conformationally 
constrained GnRH agonists ([D-Trp6,Pro9-NHEt]-GnRH and [D-Trp6,Gln8,Pro9-NHEt]-
GnRH) which are identical except for the substitution of Gln for Arg in position 8. The 
affinity of the [Gln301]-GnRHR for the constrained 01ns agonist was higher than that of the 
wildtype receptor, consistent with contact between the two residues (G1n30l_ __ Gin8 > Glu301__ 
-Gln8, table 4.1). Also, the Gln8 agonist was more potent than the Arg8 agonist in stimulating · 
IP production with the mutant [Gin301]-GnRHR (Gln30l ___ Gln8 > 01n30l ___ Arg8, table 4.1). 
This supports the proposal of contact between the position 8 residue in GnRH and the position 
301 residue of the receptor. However, in the presence of the conformational constraint, the 
apparent contribution of the Glu301 residue to the binding energy of the Arg8 agonist is much 
lower (0.02 kcaVmol) than has been reported for catalytic site ion-pair interactions (Wells et 
al., 1987). This could mean either, that there is no electrostatic interaction between these 
residues, or that the interaction occurs in an aqueous environment where hydrogen bonding of 
water plays a role in binding energies. 
Thus, the Glu301 residue is necessary for high aff"mity binding of ligands which contain 
Arg8, and which are not conformationally-constrained. However, conformationally-
constrained ligands bind both the wildtype and the mutant GnRHR with high affinity, 
regardless of whether the residue in position 8 is Arg or Gln (table 4.1). The enhancement of 
potency due to introduction of conformational constraints of the ligand is much greater in the 
mutant [Gin301]-GnRHR than in the wildtype receptor (table 4.2). The mutant receptor 
therefore prefers conformationally-constrained ligands, but cannot recognize the contribution 
of Arg8 in conforming GnRH. This suggests that the wildtype GnRHR induces the preferred 
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conformation in unconstrained ligands which contain Arg8. The [Gln301]-GnRHR is not able 
to induce this preferred conformation, but it retains a preference for the conformation 
constrained by D-amino acids in position 6. Thus, the preferred conformation of GnRH is 
probably induced by an interaction which involves Glu301 and Arg8 and this interaction is not 
required for binding of ligands which are constrained prior to their binding to the GnRHR. 
The ligand binding sites of heptahelical receptors for small ligands such as 
catecholamines are contained within the hydrophobic transmembrane helices (Dixon et al., 
1987; Strader et al., 1989; Dohlman et al., 1991). In contrast, large amino-terminal domains 
form the high affinity ligand binding sites of receptors for glycoprotein hormones (Segaloff 
and Ascoli, 1993). Peptide receptors, including the GnRHR, do not contain large amino-
terminal domains and the ligand binding sites in these receptors appear to involve residues 
both in the transmembrane helices (Zhu et al., 1992) and in the extracellular domains (Fong et 
al., 1992a, 1992c; Gether et al., 1993). We have shown that the Glu301 residue, located in the 
third extracellular loop of the GnRHR, plays a major role in determining ligand specificity. 
This confirms the importance of extracellular domain of the GnRH receptor in ligand binding. 
The Glu301 residue is conserved in the rat and mouse GnRHRs, but in sheep and human 
GnRHRs it is replaced with Asp (Illing et al., 1993). This difference indicates that the length 
of the sidechain is probably not critical for the interaction with GnRH, although it may 
contribute to some of the subtle differences in pharmacologies of mammalian GnRHRs 
(Millar et al., 1989; chapter 2). 
The [Gln301]-GnRHR shares some pharmacological characteristics with the chicken 
pituitary GnRHR in that GnRH and [Gln8]-GnRH display equal activity, while chicken 
GnRH II is more active (Millar et al., 1989; chapter 2). However, enhancement of activity 
resulting from D-amino acid substitutions in position 6 of GnRH is greater in the [Gln301]-
GnRHR (table 4.2) than in the chicken GnRHR, in agreement with suggestions that the 
chicken GnRHR does not require the same ligand conformation as is required by mammalian 
GnRHRs (Millar et al., 1989; chapter 2). These results predict that while Glu301 is likely to be 
absent from the chicken GnRHR, the latter receptor may have other features which increase 
affinity in order to compensate for the absence of Arg8 in chicken GnRHs. 
Our findings may apply to other receptors. V asopressin receptors possess an acidic 
residue in their third extracellular loop [Glu299 in the human V2 receptor (Birnbaumer et al., 
1992) and Glu323 in the rat Vl receptor (Morel et al., 1992)], which is not present at the 
corresponding position in the oxytocin receptor (Kimura et al., 1992). Since vasopressins 
possess positively charged residues (Arg. or Lys) which are replaced by neutral Leu in 
oxytocin, it is possible that a similar mechanism may determine the specificity of vasopressin 
and oxytocin receptors for their respective ligands. 
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In conclusion, we have identified a residue, Glu301, in a mammalian GnRHR which 
confers specificity for the Arg in position 8 of mammalian GnRH. This specificity may result 
from an electrostatic interaction between the two residues. Interactions which involve the 
Glu301 residue of the receptor and the Arg8 residue of the ligand appear to induc~ changes in 
the conformation of the ligand. 
CHAPTER5 
CONCLUDING DISCUSSION 
The work presented here has explored how GnRH, as a ligand, interacts with its 
receptors. At the initiation of the research, the structures of five naturally occurring forms of 
GnRH had been reported, but very little was known about the structures of the GnRH 
receptors. The different forms of GnRH were known to have different potencies in 
stimulating gonadotropin release in animals from different vertebrate classes (Millar et al., 
1986b; King and Millar, 1987). Therefore, we investigated the functional significance of each 
of the most common amino acid substitutions. Substitutions in each of the positions examined 
had significantly different consequences for GnRH potency in pituitary cells from two 
different classes of vertebrates, mammals and birds. In addition~ smaller differences in 
receptor binding affinity were demonstrated between two species of mammals. To understand 
how changes in ligand structure effect changes in receptor binding affinity and receptor 
activation, it was necessary to know the structures of the GnRH receptors. Site-directed 
mutagenesis of the cloned mouse GnRH receptor, which became available during the course 
of this work, allowed identification of a receptor residue which determines the selective 
affinity of this mammalian receptor for mammalian GnRH. A continuing project in the 
laboratory is addressing the question of how a Glu or Asp residue in the third extracellular 
loop of the mammalian GnRH receptors determines this selectivity. 
In order to study the functional significance of the amino acid substitutions which occur 
in GnRHs isolated from non-mammalian vertebrates, we synthesized chimaeric analogues 
consisting of various combinations of these substitutions. Substitution of Tyr5 with His had 
subtle effects on GnRH activity in mammals, which became apparent only when receptor 
binding affinity and gonadotropin releasing potency were considered together. Analogues 
containing His5 exhibited higher receptor binding potencies than gonadotropin releasing 
potencies. Substitution of Trp for Leu7 also resulted in minimal effects on GnRH activity. 
However, the combination of His5 and Trp 7 substitutions seems to account for the relatively 
high potency of chicken GnRH II ([His5,Trp7,Tyr8]-GnRH) compared with other position 8-
substituted GnRH analogues. Another study showed that [His5,Trp7,Leu8]-GnRH had 
relatively high GnRH potency (Folkers et al., 1986). The fact that His5 and Trp7 together 
increase GnRH activity in the presence of a hydrophobic residue in position 8, suggests that 
an interaction amongst the three sidechains accounts for the higher activity of chicken GnRH 
II in mammals. 
In contrast, in chicken pituitary cells, His5 incorporation in mammalian GnRH strongly 
decreased LH releasing potency. This substitution may cause GnRH to assume a 
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conformation which is not favoured by the chicken On.RH receptor, as the effect was reversed 
by the introduction of D-Trp in position 6. Trp substitution for Leu 7 increased LH releasing 
potency in chicken cells and could completely account for the high potency of chicken On.RH 
II compared with [Tyr8]-0nRH. In the absence of a reliable chicken GnRH receptor binding 
assay it is not possible to speculate on the mechanisms of these potency changes. 
Neutral substitutions for Arg8 had opposite effects in chicken and mammalian pituitary 
cells. Analogues with uncharged residues in position 8 exhibited high potencies in stimulating 
chicken LH release, but had low potencies in stimulating release of LH and FSH from sheep 
cells and low affinity for sheep and rat On.RH receptors. The obvious explanation of this 
result was that mammalian receptors contain a negatively charged residue which forms a salt 
bridge with the positively charged Arg in mammalian On.RH (Keinan and Hazum, 1985; 
Hazum, 1987) and that chicken On.RH receptors do not (Hasegawa et al., 1984). Testing this 
required information on the structures of the On.RH receptors. 
Attempts to purify the sheep GnRH receptor by affinity chromatography resulted in the 
purification of a protein which, although it was similar to other proteins purified by similar 
protocols (Hazum et al., 1986; Christiansen and Houen, 1994), was not the OnRH receptor. 
However, our collaboration with Dr. Sealfon's laboratory gave us access to the first On.RH 
receptor clone (Tsutsumi et al., 1992), which allowed us to test the salt bridge hypothesis by 
site-directed mutagenesis. 
We mutated acidic receptor residues located in the extracellular domain and in the 
extracellular half of the putative transmembrane domain, which could potentially be part of 
the ligand binding site. One mutant receptor exhibited decreased affinity for mammalian 
GnRH, unchanged affinity for [Oln8]-0nRH, and increased affinity for the negatively charged 
analogue [Glu8]-GnRH. Thus, substitution of the negatively charged Glu301 residue of the 
receptor removed the preference of the receptor for Arg8 in On.RH. The loss of affinity was 
specific for Arg8, since the mutant receptor retained the ability to distinguish favourable 
substitutions in positions 5, 6 and 7. These findings showed that the Glu301 residue of the 
mouse On.RH receptor plays a role in recognition of Arg8 in the ligand and were consistent 
with an electrostatic interaction between these two residues. 
These results led us to speculate that the Olu301 residue would not be conserved in the 
chicken On.RH receptor (Flanagan et al., 1994; chapter 4). However, early PCR cloning 
experiments indicate that the Olu301 residue is conserved in OnRH receptors from several 
non-mammalian vertebrate species, including the chicken (B. Blackman, Y.-M. Sun, N. Illing, 
J. Hapgood, R. P. Millar, unpublished). While this was at first surprising, studi~s with other 
peptide receptors have shown that the residues which determine ligand selectivity are located 
at different positions in different receptor subtypes (Strader et al., 1994; also see chapter 1, 
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The ligand binding domain). The differences in the sequences of the naturally occurring 
GnRHs are similar to the differences in the structures of families of peptides (e.g. 
neurokinins, endothelins) which are recognized by several receptor subtypes. Thus, the 
structural relationship of non-mammalian GnRH receptors to the mammalian receptor is 
likely to be similar to the relationship between subtypes of receptors for other peptides (60 -
80% amino acid conservation). Extending this analogy leads to the prediction that while the 
Glu301 residue determines the ligand selectivity of the mammalian GnRH receptor, it 
probably will not affect the ligand selectivity of the non-mammalian receptors. The positions 
of ligand contact sites vary among different peptide receptor subtypes. Within a single 
receptor, both conserved and divergent residues appear to interact with conserved ligand 
residues (Strader et al., 1994). It has been proposed that each receptor subtype recognizes a 
different peptide conformation (Fong et al., 1992a), and this may be the reason why ligand 
contact sites vary. Indeed, the Glu301 residue of the GnRH receptor appears to have a 
significant role in recognizing or modifying GnRH conformation. 
The Glu301 residue is necessary for high affinity binding of ligands which contain Arg8, 
and which are not conformationally constrained. However, ligands which were 
conformationally constrained by the incorporation of D-Trp6 bound both the wildtype and the 
mutant [Gin301]-GnRHR with high affinity, regardless of whether the residue in position 8 
was Arg or Gln. The enhancement of potency due to introduction of conformational 
constraints of the ligand was greater in the mutant receptor than in the wildtype. The mutant 
receptor, therefore, preferred conformationally constrained ligands, but did not recognize the 
contribution of Arg8 in conforming GnRH. This suggests that the wildtype GnRH receptor 
induces the preferred conformation in unconstrained ligands which contain Arg8. The mutant 
[Gin301]-GnRHR was not able to induce this preferred conformation, but it retained a 
preference for the conformation constrained by D-amino acids in position 6. Thus, the 
preferred conformation of GnRH may be induced by an interaction which involves the Glu301 
and Arg8 residues and this interaction does not occur during binding of ligands which are 
constrained prior to their binding to the GnRHR. 
In conclusion, we have described the relationship between the known structures of 
GnRH and their function at three different GnRH receptors which were treated essentially as 
black boxes. A little light has been shone into the black boxes. in that the amino acid 
sequences of several mammalian GnRH receptors are now known and it is anticipated that the 
cloning of non-mammalian GnRH receptors will soon be reported. Several amino acid 
residues have been identified which are important_ determinants of ligand binding, the 
integrity of receptor structure and of receptor activation. We are continuing to investigate the 
nature of the interaction by which an acidic residue which we have identified in the third 
extracellular loop of the GnRH receptors determines ligand selectivity. 
CHAPTER6 
OTHER STUDIES CONDUCTED DURING THE COURSE OF THIS THESIS AND 
LIST OF PUBLICATIONS 
During the course of the work described here, I participated in several projects 
involving GnRH receptor ligand interactions, which have not been described in this thesis. 
We showed that GnRH antagonists, which have been developed in mammalian systems, are 
much less effective in cultured chicken pituitary cells and that some peptides which are 
antagonists in mammals behave as agonists in chickens (Jacobs et al., 1995). I helped 
characterize several of the cloned GnRH receptors (Tsutsumi et al., 1992; Chi et al., 1993; 
Illing et al., 1994) and also participated in studies which used the cloned receptors to examine 
the structure of the receptor and how it interacts with ligands. We showed that the mouse 
GnRH receptor is glycosylated at two of its three glycosylation consensus sequences when it 
is expressed in COS-1 cells and found that glycosylation affects expression of the receptor, 
but does not affect ligand binding affinity (Davidson et al., 1995). Compared with other 
GPCRs, the GnRH receptor appears to have interchanged two highly conserved residues, an 
Asp which usually occurs in the second transmembrane helix and an Asn which usually 
occurs in the seventh. We used this natural reciprocal mutation to show that the sidechains of 
these two residues have complimentary roles in maintaining receptor structure and occupy the 
same microenvironment within the receptor (Zhou et al., 1994). We are continuing to explore 
this interaction which is discussed in more detail in chapter 1. Comparison of the GnRH 
' receptor with other GPCRs also allowed us to identify the Lys121 residue which has a role in 
binding of GnRH agonists but not GnRH antagonists. 
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